Cationic lipid, liposome, lipid nanoparticle and application
Patent Information
- Application Number
- CN202380032078.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-04-02
- Filing Date
- 2023-04-03
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2043-04-03
AI Technical Summary
In existing gene therapy, cationic liposomes and lipid nanoparticles have deficiencies in targeting, side effects, and transfection efficiency, making it difficult to effectively deliver nucleic acid drugs.
A cationic lipid with a specific structure was developed to form efficient liposomes or lipid nanoparticles by complexing with neutral auxiliary lipids and other materials for improving transfection efficiency and targeting.
It achieves efficient delivery of nucleic acid drugs, improves transfection efficiency and targeting, reduces side effects, and is suitable for nucleic acid drug delivery in gene therapy.
Smart Images

Figure CN118974004A_ABST
Abstract
Description
Cationic lipids, liposomes, lipid nanoparticles and uses
[0001] This disclosure claims priority to Chinese patent application No. 202210349570.6 filed on April 2, 2022, and the contents of the above-mentioned Chinese patent application disclosure are hereby cited in their entirety as part of this disclosure. Technical Field
[0002] The present disclosure generally relates to the field of gene therapy pharmaceutical preparations, and more specifically, to a cationic lipid for forming liposomes or lipid nanoparticles. The present disclosure also relates to liposomes containing the cationic lipid and uses of the cationic lipid. Background Art
[0003] In recent years, with the deepening of our understanding of disease pathogenesis at the cellular level, gene therapy has become a hot research topic. Various genetically engineered drugs have been continuously developed and commercialized.
[0004] In gene therapy, gene transfer vectors are crucial for delivering exogenous genes into recipient cells. Cationic liposomes and lipid nanoparticles are gaining increasing attention due to their superior targeting, minimal side effects, excellent stability, and high transfection efficiency. Cationic liposomes and lipid nanoparticles are typically constructed by combining cationic lipids with neutral helper lipids and other materials under appropriate conditions. Their transfection efficiency is related to the structure of the cationic lipids used.
[0005] Summary of the Invention
[0006] At least one embodiment of the present disclosure provides a cationic lipid having the following general formula (I):
[0007] wherein A is selected from methine and nitro, wherein the methine is optionally unsubstituted or replaced by R a replace;
[0008] Among them, when A is methine, B is R 1 -L 1 -Y 1 -L 2 -,in
[0009] R 1 R 2 R 3 N-, where R 2 and R 3 Each is independent of C 1-6 alkyl,
[0010] or R 1 is a 5- or 6-membered heterocyclic group containing 1 or 2 ring nitrogen atoms,
[0011] wherein the C 1-6 The alkyl group or the 5- or 6-membered heterocyclic group are each independently unsubstituted or substituted by 1-3 R b replace;
[0012] L 1 and L 2 Each independently selected from a chemical bond and a linear or branched C 1-12 Alkylene, the C 1-12 Each occurrence of alkylene is optionally unsubstituted or substituted with 1-3 R c Replacement; and
[0013] Y 1 is selected from the group consisting of -C(=X)-X-, -XC(=X)-, -C(=X)-NH-, -NH-C(=X)-, -XC(=X)-NH-, -NH-C(=X)-X-, -XC(=X)-X-, -NH-C(=X)-NH-, and -XX-; and
[0014] When A is a nitro group, B is C 1-6 Alkyl, wherein the C 1-6 The alkyl group is optionally unsubstituted or substituted with 1-3 R d replace;
[0015] C is -L 3 -Y 2 -L 4 -CH=CR 4 R 5 ,in
[0016] L 3 and L 4 Each independently selected from a chemical bond and a linear or branched C 1-12 Alkylene, the C 1-12 Each occurrence of alkylene is optionally unsubstituted or substituted with 1-3 R e replace,
[0017] Y 2 is selected from -C(=X)-X-, -XC(=X)-, -C(=X)-NH-, -NH-C(=X)-, -XC(=X)-NH-, -NH-C(=X)-X-, -XC(=X)-X-, -NH-C(=X)-NH- and -XX-, and
[0018] R 4 and R 5 Each independently selected from a linear or branched C 2-12 Alkyl, the C 2-12 The alkyl group is optionally unsubstituted or substituted with 1-3 R f replace;
[0019] D is -L 5 -Y 3 -L 6 -R 6 ,in
[0020] L 5 and L 6 Each independently selected from a chemical bond and a linear or branched C 1-12 Alkylene, the C 1-12 Each occurrence of alkylene is optionally unsubstituted or substituted with 1-3 R g replace,
[0021] Y 3 is selected from -C(=X)-X-, -XC(=X)-, -C(=X)-NH-, -NH-C(=X)-, -XC(=X)-NH-, -NH-C(=X)-X-, -XC(=X)-X-, -NH-C(=X)-NH- and -XX-, and
[0022] R 6 Independently selected from saturated or unsaturated linear or branched C 6-18 Hydrocarbon or steroid group, the C 6- 18 The hydrocarbon or steroid group is optionally unsubstituted or substituted with 1-3 R h replace;
[0023] Or, D is -L 3 -Y 2 -L 4 -CH=CR 4 R 5 ;
[0024] Each occurrence of X is independently O or S, and
[0025] R a 、R b 、R c 、R d 、R e 、R f 、R g and R h Each occurrence is independently selected from C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylamino, di(C 1-3 Alkyl)amino, C 1-3 Alkoxycarbonyl, C 1-3 Alkylcarbonyloxy, C 1-3 Alkylcarbonylamino, C 1-3 alkylaminocarbonyl, hydroxy, halogen and cyano.
[0026] In one aspect, in the cationic lipid of formula (I), X is O.
[0027] On the other hand, in the cationic lipid represented by formula (I), B is R 1 -L 1 -Y 1 -L 2 -, R 1 R 2 R 3 N-, and R 2 and R 3 Each is independent of C 1-6 Alkyl, the C 1-6 Alkyl is optionally unsubstituted or substituted with 1-3 groups independently selected from C 1-3 Alkyl, C 1-3 Substituents include alkoxy, hydroxy and halogen.
[0028] On the other hand, in the cationic lipid represented by formula (I), R 2 and R 3 are the same or different and are each independently selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, isopropyl and tert-butyl.
[0029] On the other hand, in the cationic lipid represented by formula (I), B is R 1 -L 1 -Y 1 -L 2 -, R 1 is a 5- or 6-membered heterocyclic group containing 1 or 2 ring nitrogen atoms, and the 5- or 6-membered heterocyclic group is unsubstituted or optionally substituted by 1-3 C 1-3 Alkyl-substituted saturated 5- or 6-membered heterocyclic group.
[0030] On the other hand, in the cationic lipid represented by formula (I), the 5- or 6-membered heterocyclic group is selected from N-methyl-piperidin-4-yl, N-methyl-piperidin-2-yl, N-methyl-pyrrolidin-2-yl, N-ethyl-piperidin-4-yl, N-ethyl-piperidin-2-yl, N-ethyl-pyrrolidin-2-yl and piperidin-1-yl.
[0031] On the other hand, in the cationic lipid represented by formula (I), B is C which is unsubstituted or substituted with 1-3 substituents selected from hydroxyl, halogen and cyano. 2-4 alkyl.
[0032] In another aspect, in the cationic lipid of formula (I), B is selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl and tert-butyl substituted with a primary hydroxyl group.
[0033] On the other hand, in the cationic lipid represented by formula (I), C is -L 3 -Y 2 -L 4 -CH=CR 4 R 5 , where R 4 and R 5 are the same or different and are each independently selected from a linear C 2-12 alkyl.
[0034] On the other hand, in the cationic lipid represented by formula (I), D is -L 5 -Y 3 -L 6 -R 6 , and R 6 It is a straight or branched chain C containing one or two carbon-carbon double bonds. 6-18 Hydrocarbon group.
[0035] On the other hand, in the cationic lipid represented by formula (I), R 6 A straight or branched C 6-18 Hydrocarbon group.
[0036] On the other hand, in the cationic lipid represented by formula (I), D is -L 5 -Y 3 -L 6 -R 6 , and R 6 To be C 1-6 Alkoxycarbonyl substituted C 6-18 alkyl.
[0037] On the other hand, in the cationic lipid represented by formula (I), D is -L 3 -Y 2 -L 4 -CH=CR 4 R 5 , where R 4 and R 5 are the same or different and are each independently selected from a linear C 2-12 alkyl.
[0038] On the other hand, in the cationic lipid represented by formula (I), L 1 , L 2 , L 3 , L 4 , L 5 and L 2 Each independently selected from a chemical bond and C 1-6 Alkylene, the C 1-6 Alkylene is optionally unsubstituted or substituted by 1-3 groups independently selected from C 1-3Alkyl, C 1-3 Substituents include alkoxy, hydroxy and halogen.
[0039] On the other hand, in the cationic lipid represented by formula (I), L 1 , L 2 , L 3 , L 4 , L 5 and L 2 Each independently selected from a chemical bond and an unsubstituted C 1-6 Alkylene.
[0040] On the other hand, in the cationic lipid represented by formula (I), Y 1 、Y 2 and Y 3 Each is independently selected from -OC(=O)-, -C(=O)-O- and -OC(=O)-.
[0041] On the other hand, the cationic lipid represented by formula (I) has a structure selected from the group consisting of:
[0042] At least one embodiment of the present disclosure further discloses a liposome comprising the cationic lipid according to any embodiment of the present disclosure.
[0043] At least one embodiment of the present disclosure further discloses a lipid nanoparticle comprising the cationic lipid according to any embodiment of the present disclosure.
[0044] At least one embodiment of the present disclosure further discloses use of the cationic lipid according to at least one embodiment of the present disclosure for preparing liposomes.
[0045] At least one embodiment of the present disclosure further discloses use of the cationic lipid according to at least one embodiment of the present disclosure for preparing lipid nanoparticles. DETAILED DESCRIPTION
[0046] For the purpose of the following detailed description, it should be understood that the present disclosure can adopt various alternative variations and step sequences, unless expressly provided otherwise. In addition, except in any operating examples, or when otherwise indicated, all numerals representing the amount of the components used in the specification and claims should be understood to be modified by the term "about" in all cases. Therefore, unless otherwise indicated, the numerical parameters set forth in the following specification and the appended claims are approximate values that vary according to the desired performance to be obtained by the present disclosure. At least it is not intended to limit the application of the doctrine of equivalents to the scope of the claims, and each numerical parameter should at least be interpreted according to the number of reported significant figures and by applying ordinary rounding techniques.
[0047] Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the disclosure are approximations, the numerical values set forth in the specific examples are reported as precisely as possible. Any numerical value, however, inherently contains certain errors necessarily resulting from the standard deviation found in their respective testing measurements.
[0048] Furthermore, it should be understood that any numerical range recited herein is intended to include all subranges subsumed therein. For example, a range of "1 to 10" is intended to include all subranges between (and including) the recited minimum value of 1 and the recited maximum value of 10, i.e., having a minimum value equal to or greater than 1 and a maximum value equal to or less than 10.
[0049] In this disclosure, unless otherwise expressly stated, the use of the singular includes the plural and the plural includes the singular. Furthermore, in this disclosure, unless otherwise expressly stated, the use of "or" means "and / or," even though "and / or" could be explicitly used in certain circumstances. Furthermore, in this disclosure, unless otherwise expressly stated, the use of "a" or "an" means "at least one." For example, "a" compound, "a" composition, etc., refers to one or more of any of these items.
[0050] The disclosed compounds can be synthesized by synthetic routes comprising methods similar to those known in the chemical field, particularly with reference to the descriptions contained herein. Starting materials are generally available from commercial sources or can be easily prepared using methods well known to those skilled in the art. For illustrative purposes, the reaction schemes depicted below show possible routes for synthesizing the disclosed compounds and key intermediates. To describe each reaction step in more detail, see the Examples section below. Those skilled in the art will appreciate that other suitable starting materials, reagents, and synthetic routes can be used to synthesize the disclosed compounds and their various derivatives. In addition, with reference to the present disclosure, the various compounds prepared by the following methods can be further modified using conventional chemical methods well known to those skilled in the art.
[0051] The compounds of the present disclosure may include stereoisomers (e.g., cis and trans isomers), optical isomers (e.g., R and S enantiomers), tautomers (e.g., tautomers of enol and imine forms and tautomers of keto and enamine forms), atropisomers (i.e., isomers with restricted rotation), and the like of the compounds of the present disclosure.
[0052] For purposes of the present invention as described and claimed herein, the following terms are defined as follows:
[0053] As used herein, the term "cationic lipid" refers to a class of lipid materials that are charged under physiological conditions, which can be used to prepare liposomes for delivering nucleic acid drugs. As used herein, the term "nucleic acid drug" is also known as "nucleotide drug", which refers to a variety of ribonucleic acid (RNA) drugs and / or deoxyribonucleotide (DNA) drugs with different functions, which mainly play a role at the gene level. Examples of nucleic acid drugs can include, but are not limited to, RNA nucleic acid drugs, such as transfer RNA (tRNA), small interfering RNA (siRNA), antisense oligonucleotides (Antisense Oligonucleotide), microRNA (miRNA), long non-coding RNA (lncRNA), nucleic acid aptamers (Apatmer), messenger RNA (mRNA), circular RNA (circRNA), self-replicating RNA (self-replicating RNA), etc.; and DNA nucleic acid drugs, such as plasmids, linearized plasmids, nanoplasmids (nanoplasmid), "dog bone" DNA (doggyboneDNA), closed-end RNA (closed-ended DNA), oligomeric DNA (oligoDNA), etc. Currently, nucleic acid drugs can be used as drugs for the treatment or prevention of diseases including but not limited to tumors, autoimmune diseases, infectious diseases, etc. For example, they can be used as tumor targeted therapeutic agents, new coronavirus vaccines, etc.
[0054] As used herein, the term "liposome" generally refers to the closed vesicle with a bilayer structure formed when lipids (lipidoids) and additives are dispersed in an aqueous phase, which can usually fuse with cell membranes to deliver bioactive substances (such as nucleic acid drugs or other drugs) to the interior of the cell. In general, the basic structure of cationic lipids is composed of a positively charged polar head (polar head) and one or more hydrophobic tails (hydrophobic tail). The positively charged polar head group generally includes amines (primary amines, secondary amines, tertiary amines, quaternary ammonium salts), guanidines, amidines, etc., which can form complexes with negatively charged nucleic acids through electrostatic interaction and enter cells through the endocytosis of cells. The hydrophobic tail can generally be a saturated / or unsaturated fatty hydrocarbon chain or a cholesterol group, which can affect the pKa, lipophilicity, fluidity and fusogenicity of the cationic lipid, thereby affecting the formation and effectiveness of cationic liposomes. Between the positively charged polar head group and the hydrophobic tail, a linker can also be included, which can connect the head to the tail, or can be hidden in the tail. Linkers can be divided into non-biodegradable linkers (such as ethers) and biodegradable linkers (such as esters, amides, and thiols), which can affect the stability, biodegradability, cytotoxicity, and transfection efficiency of cationic liposomes. Cationic lipids can be considered as multicomponent molecules, each of which requires precise design for safe and effective packaging and delivery of nucleic acids.
[0055] As used herein, the term "lipid nanoparticles (LNP)" refers to a class of nanocarriers developed on the basis of liposomes for delivering nucleic acid substances to cells, typically consisting of cationic lipids, neutral auxiliary phospholipids, cholesterol, and PEG lipids. Lipid nanoparticles are one of the important technologies in lipid carrier drug delivery systems and have become an important advance in nucleic acid-based therapeutic drugs. Oligonucleotides encapsulated in lipid nanoparticles are protected from enzymatic degradation during delivery and are effectively delivered to cells, where the contents of the carrier particles are released and translated into therapeutic proteins.
[0056] Unless otherwise indicated, the term "hydrocarbyl" as used herein refers to a monovalent chain group consisting of carbon atoms and hydrogen atoms. A hydrocarbyl group may be straight or branched, saturated or unsaturated, and may be substituted or unsubstituted. Non-limiting examples of hydrocarbyl groups include, but are not limited to, alkyl, alkenyl, or alkynyl groups. For example, the term "C 2-18 "Hydrocarbyl" refers to a monovalent straight or branched chain alkyl, alkenyl or alkynyl group having 2 to 18 carbon atoms. 2-18Non-limiting examples of hydrocarbon groups can include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl, neopentyl, hexyl, heptyl, octyl, nonyl, decyl, lauryl, butenyl, hexenyl, octenyl, decenyl, myrcenyl, 1,3-butadienyl, 1,3-pentadienyl, octynyl, and the like.
[0057] Unless otherwise indicated, the term "alkyl" as used herein refers to a group of the formula C n H2 n+1 - is a saturated monovalent hydrocarbon chain, wherein n is an integer between 1 and 18. The alkyl group may be straight or branched, and may be substituted or unsubstituted. For example, the term "C 1-6 "Alkyl" refers to a monovalent straight or branched hydrocarbon group containing 1 to 6 carbon atoms. 1-6 The non-limiting example of alkyl includes but is not limited to methyl, ethyl, propyl group, isopropyl, sec-butyl, the tert-butyl, n-propyl, normal-butyl, isobutyl, sec-butyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, neopentyl, 3,3-dimethylpropyl, 2-methylpentyl, hexyl etc.Alkyl moiety can be connected to another chemical part by any one carbon atom on the carbochain.As described herein, alkyl can be optionally substituted.In addition, when being used for compound word such as alkyloxy (alkoxy), described alkyl moiety has the identical meaning as in the disclosure, and can be connected to another chemical part by any one carbon atom on the carbochain.
[0058] Unless otherwise indicated, the term "alkenyl" as used herein refers to a straight or branched aliphatic hydrocarbon chain having 2 to 18 carbon atoms and containing at least one carbon-carbon double bond (e.g., -CH=CH-, -CH=CH2). Non-limiting examples of alkenyl groups include ethenyl, 1-propenyl, 2-propenyl, isopropenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-pentenyl, hexenyl, octenyl, decenyl, myrcenyl, 1,3-butadienyl, 1,3-pentadienyl, and the like.
[0059] Unless otherwise indicated, the term "alkynyl" as used herein refers to a straight or branched aliphatic hydrocarbon chain having 2 to 18 carbon atoms and containing at least one carbon-carbon triple bond (e.g., -C≡C- or -C≡CH). Non-limiting examples of alkynyl groups include: ethynyl, 2-propynyl, 1-methyl-2-propynyl, 2-butynyl, 3-butynyl, 2-methyl-3-butynyl, and the like.
[0060] Unless otherwise indicated, the term "alkylene" as used herein refers to a group of the formula -C n H 2n - is a saturated divalent chain hydrocarbon group, wherein n is an integer between 1 and 18. The alkylene group may be straight or branched, and may be substituted or unsubstituted. For example, the term "C1-12 "Alkylene" refers to a saturated divalent straight or branched hydrocarbon group containing 1 to 12 carbon atoms. 1-12 The non-limiting examples of alkylene groups include but are not limited to methylene, ethylene, propylene, butylene, hexylene, octylene, decylene, 2-ethylhexyl etc. The alkylene moiety can be connected to another chemical part by any one carbon atom on the carbon chain. As described herein, alkylene groups can be optionally substituted.
[0061] As used herein, unless otherwise indicated, the term "methine" refers to a -CH< group, wherein the -CH< group may be optionally unsubstituted or substituted; and the term "nitro" refers to a -N< group.
[0062] As used herein, unless otherwise indicated, the term "halogen" refers to fluorine, chlorine, bromine, or iodine.
[0063] As used herein, unless otherwise indicated, the term "hydroxy" refers to an -OH group.
[0064] As used herein, unless otherwise indicated, the term "alkoxy" refers to an alkyl-O- group, wherein alkyl is as defined in this disclosure.
[0065] As used herein, unless otherwise indicated, the term "amino" refers to a -NH2 group.
[0066] As used herein, unless otherwise indicated, the term "alkylamino" refers to an alkyl-NH- group; the term "dialkylamino" refers to an (alkyl)2-N- group, wherein alkyl is as defined in this disclosure.
[0067] As used herein, unless otherwise indicated, the term "cyano" refers to a -C≡N group.
[0068] As used herein, unless otherwise indicated, the term "carbonyl" refers to a -(C=O)- group.
[0069] As used herein, unless otherwise indicated, the term "carbonyloxy" refers to a -C(=O)-O- or a -OC(=O)- group.
[0070] As used herein, unless otherwise indicated, the term "alkoxycarbonyl" refers to an alkyl-OC(=O)- group, wherein alkyl is as defined in this disclosure.
[0071] Unless otherwise indicated, the term "steroid group" as used herein refers to a group containing a cyclopentanol-fused perhydrophenanthrene structure or a structure derived from cyclopentanol-fused perhydrophenanthrene.
[0072] In one embodiment of the present disclosure, a cationic lipid is provided having the following general formula (I):
[0073] wherein A is selected from methine and nitro, wherein the methine may be optionally unsubstituted or replaced by R a replace;
[0074] Among them, when A is methine, B is R 1 -L 1 -Y 1 -L 2 -,in
[0075] R 1 R 2 R 3 N-, where R 2 and R 3 Each is independent of C 1-6 alkyl,
[0076] or R 1 is a 5- or 6-membered heterocyclic group containing 1 or 2 ring nitrogen atoms,
[0077] wherein the C 1-6 The alkyl group or the 5- or 6-membered heterocyclic group are each independently unsubstituted or substituted by 1-3 R b replace;
[0078] L 1 and L 2 Each independently selected from a chemical bond and a linear or branched C 1-12 Alkylene, the C 1-12 Each occurrence of alkylene is optionally unsubstituted or substituted with 1-3 R c Replacement; and
[0079] Y 1 is selected from the group consisting of -C(=X)-X-, -XC(=X)-, -C(=X)-NH-, -NH-C(=X)-, -XC(=X)-NH-, -NH-C(=X)-X-, -XC(=X)-X-, -NH-C(=X)-NH-, and -XX-; and
[0080] When A is a nitro group, B is C 1-6 Alkyl, wherein the C 1-6 The alkyl group is optionally unsubstituted or substituted with 1-3 R d replace;
[0081] C is -L 3 -Y 2 -L 4 -CH=CR 4 R 5 ,in
[0082] L 3 and L 4 Each independently selected from a chemical bond and a linear or branched C1-12 Alkylene, the C 1-12 Each occurrence of alkylene is optionally unsubstituted or substituted with 1-3 R e replace,
[0083] Y 2 is selected from -C(=X)-X-, -XC(=X)-, -C(=X)-NH-, -NH-C(=X)-, -XC(=X)-NH-, -NH-C(=X)-X-, -XC(=X)-X-, -NH-C(=X)-NH- and -XX-, and
[0084] R 4 and R 5 Each independently selected from a linear or branched C 2-12 Alkyl, the C 2-12 The alkyl group is optionally unsubstituted or substituted with 1-3 R f replace;
[0085] D is -L 5 -Y 3 -L 6 -R 6 ,in
[0086] L 5 and L 6 Each independently selected from a chemical bond and a linear or branched C 1-12 Alkylene, the C 1-12 Each occurrence of alkylene is optionally unsubstituted or substituted with 1-3 R g replace,
[0087] Y 3 is selected from -C(=X)-X-, -XC(=X)-, -C(=X)-NH-, -NH-C(=X)-, -XC(=X)-NH-, -NH-C(=X)-X-, -XC(=X)-X-, -NH-C(=X)-NH- and -XX-, and
[0088] R 6 Independently selected from saturated or unsaturated linear or branched C 2-12 Hydrocarbon or steroid group, the C 2- 12 The hydrocarbon or steroid group is optionally unsubstituted or substituted with 1-3 R h replace;
[0089] Or, D is -L 3 -Y 2 -L 4 -CH=CR 4 R 5 ;
[0090] Each occurrence of X is independently O or S, and
[0091] R a 、R b 、R c 、R d 、R e 、R f 、R g and R h Each occurrence is independently selected from C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylamino, di(C 1-3 Alkyl)amino, C 1-3 Alkoxycarbonyl, C 1-3 Alkylcarbonyloxy, C 1-3 Alkylcarbonylamino, C 1-3 alkylaminocarbonyl, hydroxy, halo and cyano.
[0092] In some aspects of the present disclosure, in the cationic lipid represented by formula (I), A may be a methine group. Alternatively, in another aspect of the present disclosure, A may be a nitrilo group.
[0093] In another aspect of the present disclosure, in the cationic lipid represented by formula (I), X may be O or S. For example, X may be O.
[0094] In another aspect of the present disclosure, in the cationic lipid represented by formula (I), A is a methine, B can be R 1 -L 1 -Y 1 -L 2 -, where R 1 Can be R 2 R 3 N-, and R 2 and R 3 may be each independently optionally unsubstituted or substituted by 1-3 independently selected 1-3 Alkyl, C 1-3 Alkoxy, hydroxy and halogen substituted C 1-6 Alkyl. For example, R 2 and R 3 Each of them may be independently unsubstituted or substituted by 1-3 independently selected 1-3 Alkyl, C 1-3 Alkoxy, hydroxy and halogen substituted C 2-4 Alkyl, for example, methyl, ethyl, n-propyl, isopropyl, chloromethyl, chloroethyl, chloropropyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, methoxymethyl, methoxyethyl, etc. In some aspects of the present disclosure, R 2 and R 3and R are the same and may be methyl, ethyl, n-propyl, isopropyl, n-butyl, isopropyl or tert-butyl. 2 and R 3 may be different and each independently selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, isopropyl or tert-butyl.
[0095] Alternatively, in another aspect of the present disclosure, in the cationic lipid represented by formula (I), A is a methine group, and B can also be R 1 -L 1 -Y 1 -L 2 -, where R 1 It may be unsubstituted or optionally substituted with 1 to 3 C 1-3 Alkyl-substituted saturated 5- or 6-membered heterocyclic group. For example, R 1 It can be selected from N-methyl-piperidin-4-yl, N-methyl-piperidin-2-yl, N-methyl-pyrrolidin-2-yl, N-ethyl-piperidin-4-yl, N-ethyl-piperidin-2-yl, N-ethyl-pyrrolidin-2-yl and piperidin-1-yl.
[0096] In another aspect of the present disclosure, in the cationic lipid represented by formula (I), A is a nitrilo group, B can be C which is unsubstituted or substituted with 1-3 substituents selected from hydroxyl, halogen and cyano groups. 2-4 For example, B can be selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl and tert-butyl substituted with a primary hydroxyl group.
[0097] In another aspect of the present disclosure, in the cationic lipid represented by formula (I), C may be -L 3 -Y 2 -L 4 -CH=CR 4 R 5 , where R 4 and R 5 can be the same or different and are each independently selected from linear C 2-12 alkyl.
[0098] In another aspect of the present disclosure, in the cationic lipid represented by formula (I), D may be -L 5 -Y 3 -L 6 -R 6 , where R 6 It is a straight or branched chain C containing one or more carbon-carbon double bonds. 6-18 Hydrocarbyl; or, R 6 It can be a straight chain or branched chain containing two carbon-carbon double bonds. 6-18 Hydrocarbyl; or, R 6Can be C 1-6 Alkoxycarbonyl substituted C 6-18 alkyl.
[0099] In an alternative embodiment, in the cationic lipid represented by formula (I), D can be -L 3 -Y 2 -L 4 -CH=CR 4 R 5 , where R 4 and R 5 are the same or different and are each independently selected from a linear C 2-12 For example, in some cases, C and D can be the same.
[0100] In another aspect of the present disclosure, in the cationic lipid represented by formula (I), L 1 , L 2 , L 3 , L 4 , L 5 and L 6 can be independently selected from chemical bonds and C 1-8 Alkylene, wherein the C 1-8 Alkylene is optionally unsubstituted or substituted by 1-3 groups independently selected from C 1-3 Alkyl, C 1-3 Alkoxy, hydroxy and halogen substituents. In some cases, L 1 , L 2 , L 3 , L 4 , L 5 and L 6 can be independently selected from chemical bonds and unsubstituted C 1-8 Alkylene groups include, for example, a chemical bond, methylene, ethylene, propylene, butylene, pentamethylene, hexamethylene, heptamethylene, octamethylene, and 2,2-dimethyl-propylenediyl.
[0101] In another aspect of the present disclosure, in the cationic lipid represented by formula (I), Y 1 、Y 2 and Y 3 Y may be independently selected from -C(=X)-X-, -XC(=X)-, -C(=X)-NH-, -NH-C(=X)-, -XC(=X)-NH-, -NH-C(=X)-X-, -XC(=X)-X-, -NH-C(=X)-NH-, and -XX-, wherein each occurrence of X may be independently O or S. In some cases, X may be O, and Y 1 、Y 2 and Y 3Each of the following may be independently selected from -C(=O)-O-, -OC(=O)-, -C(=O)-NH-, -NH-C(=O)-, -OC(=O)-NH-, -NH-C(=O)-O-, -OC(=O)-O-, -NH-C(=O)-NH-, and -OO-. For example, Y 1 、Y 2 and Y 3 They may be each independently selected from -C(=O)-O-, -OC(=O)- and -OC(=O)-O-.
[0102] In some aspects of the present disclosure, the cationic lipid represented by formula (I) may have a structure selected from the group consisting of:
[0103] At least one embodiment of the present disclosure further discloses a liposome comprising any one of the above-mentioned cationic lipids.
[0104] At least one embodiment of the present disclosure also discloses a lipid nanoparticle comprising any one of the above-mentioned cationic lipids.
[0105] At least one embodiment of the present disclosure further discloses use of any of the above-mentioned cationic lipids for preparing liposomes.
[0106] At least one embodiment of the present disclosure also discloses use of any of the above-mentioned cationic lipids for preparing lipid nanoparticles.
[0107] The liposomes or lipid nanoparticles according to at least one embodiment of the present disclosure can be used to encapsulate and deliver various nucleic acid drugs, including but not limited to RNA-based nucleic acid drugs, such as tRNA, siRNA, antisense oligonucleotides, microRNA, lncRNA, nucleic acid aptamers, mRNA, circular RNA, self-replicating RNA, etc.; and DNA-based nucleic acid drugs, such as plasmids, linearized plasmids, nanoplasmids, "dog bone" DNA, blocked-end RNA, oligomeric DNA, etc. In some examples, the liposomes or lipid nanoparticles according to the present disclosure can be used to deliver nucleic acid drugs for the treatment or prevention of diseases including but not limited to tumors, autoimmune diseases, infectious diseases, etc., such as for the delivery of tumor-targeted therapeutic agents, new crown vaccines, etc.
[0108] Example
[0109] The following examples provide a more detailed description of the preparation, characterization and properties of the compounds of the present invention. However, it is to be understood that the invention as fully described and set forth in the claims is not intended to be limited to the details of the following schemes or modes of preparation.
[0110] abbreviation:
[0111] The following abbreviations are used in the following examples:
[0112] rt: room temperature;
[0113] h / hr: hours
[0114] EA: ethyl acetate;
[0115] PE: petroleum ether;
[0116] DCM: dichloromethane;
[0117] DIEA: diisopropylethylamine;
[0118] EDCI: 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride;
[0119] DMAP: 4-dimethylaminopyridine;
[0120] THF: tetrahydrofuran;
[0121] tBuONa: sodium tert-butyl oxide;
[0122] tBuOK: potassium tert-butoxide;
[0123] MeOH: methanol;
[0124] TsOH: p-toluenesulfonic acid;
[0125] TfOH: trifluoroethanesulfonic acid;
[0126] ACN: acetonitrile;
[0127] DMF: N,N-dimethylformamide;
[0128] DMSO: dimethyl sulfoxide;
[0129] EtOH: ethanol;
[0130] NaH: sodium hydride;
[0131] DCC: dicyclohexylcarbodiimide;
[0132] TEA: triethylamine;
[0133] TsOH: p-toluenesulfonic acid;
[0134] NaOH: sodium hydroxide;
[0135] LiOH: lithium hydroxide;
[0136] NaI: sodium iodide;
[0137] K2CO3: potassium carbonate;
[0138] DSPC = distearoylphosphatidylcholine;
[0139] DMG-PEG2000 = 1,2-dimyristoyl-1,2-C-glycerol-3-methoxypolyethylene glycol-2000;
[0140] FFluc = firefly luciferase;
[0141] LNP = liposomal nanoparticle;
[0142] PDI = polydispersity index;
[0143] pKa = dissociation constant.
[0144] Preparation Example
[0145] Example 1: Preparation of 3-(((3-(diethylamino)propyloxy)carbonyl)oxy)-2-(((3-nonyldodec-2-enoyl)oxy)methyl)propyl (9Z,12Z)-octadec-9,12-dienoate (CPL-001-01)
[0146] Preparation of ethyl 3-nonyldodec-2-enoate (mixture 2)
[0147] Under N2 atmosphere, tBuONa (14.4g, 150mmol, 2.5 equivalents) was added to a mixture of ethyl 2-(diethoxyphosphono)acetate (33.6g, 150mmol, 2.5 equivalents) in THF (200mL) at 0°C, followed by compound 1 (16.92g, 60mmol, 1.0 equivalents) in THF (136mL). The reaction was then stirred at reflux for 16 hours. 100mL of water was added to the compound and extracted with EA (50mL x 3) and washed with a NaCl aqueous solution (50mL x 3). The organic layer was dried over Na2SO4, filtered, concentrated, and purified by column chromatography on silica gel (PE:EA=300 / 1) to give compound 2 (12.8g, 60.6% yield) as a colorless oil.
[0148] Preparation of 3-nonyldodec-2-enoic acid (Compound 3)
[0149] Under N2 atmosphere, NaOH (5.31 g, 132.8 mmol, 4.0 equivalents) was added to a mixture of 3-nonyl dodec-2-enoic acid ethyl ester (18 g, 33.21 mmol, 1.0 equivalents) in ethanol / water (180 mL / 180 mL) at 0 ° C. The reaction mixture was refluxed for 16 hours. The solvent was evaporated and the pH was adjusted to 4-5 with 1N HCl, extracted with EA (120 mL x 3), and washed with a NaCl aqueous solution (120 mL). The organic layer was dried over Na2SO4, filtered, concentrated, and purified on silica gel by column chromatography (PE: EA = 150 / 1) to give compound 3 (5.16 g, 30.2% yield) as a colorless oil.
[0150] 1 H NMR (400MHz, CDCl3) δ5.64(s,1H),2.65-2.55(m,2H),2.20-2.11(m,2H),1.46-1.26(m,28H),0.91-0.85(m,6H).
[0151] Preparation of 3-hydroxy-2-(((3-nonyldodec-2-enoyl)oxy)methyl)propyl(9Z,12Z)-octadec-9,12-dienoate (Compound 5)
[0152] Under N2 atmosphere, DIEA (2.11 g, 16.32 mmol, 4.0 equiv), EDCI (1.18 g, 6.12 mmol, 1.5 equiv) and DMAP (100 mg, 0.82 mmol, 0.2 equiv) were added to a solution of compound 3 (1.32 g, 4.08 mmol, 1.0 equiv) in DCM (10 mL) at 0 ° C. Subsequently, a solution of compound 4 (1.5 g, 4.08 mmol, 1.0 equiv) in DCM (5 mL) was added. The reaction mixture was stirred at 30 ° C for 16 hours. 50 mL of water was added to the mixture and extracted with DCM (50 mL x 3) and washed with NaCl aqueous solution (100 mL). The organic layer was dried over Na2SO4, filtered, concentrated, and purified on silica gel by column chromatography (PE: EA = 6 / 1) to give compound 5 (1.53 g, 55.6% yield) as a colorless oil.
[0153] 1H NMR (400MHz, CDCl3) δ5.62(s,1H),5.42-5.26(m,4H),4.30-4.08(m,4H),3.68-3.54(m,2H),2.82-2.72(m,2H),2.64-2.52( m,2H),2.36-2.31(m,2H),2.17-2.10(m,2H),2.09-2.01(m,4H),1.66-1.57(m,2H),1.46-1.23(m,43H),0.91-0.85(m,9H).
[0154] Preparation of ethyl 3-nonyldodec-2-enoate (CPL-001-01)
[0155] To a solution of compound 5 (700 mg, 1.038 mmol, 1.0 equiv) in DCM (10 mL) was added pyridine (820 mg, 10.38 mmol, 10.0 equiv) and triphosgene (122 mg, 0.416 mmol, 0.4 equiv) at 0°C under a N2 atmosphere. The reaction mixture was then stirred at 0°C for 0.5 hours. A solution of 3-(diethylamino)propan-1-ol (408 mg, 3.114 mmol, 3.0 equiv) in DCM (1 mL) was then added at 0°C. The reaction mixture was stirred at 30°C for 16 hours. 20 mL of water was added to the mixture, and the mixture was extracted with DCM (20 mL x 3) and washed with aqueous NaCl solution (50 mL). The organic layer was dried over Na2SO4, filtered, concentrated, and purified by reverse phase chromatography to give the target CPL-001-01 (101 mg, 11.6% yield) as a colorless oil.
[0156] LCMS: LC / MS (ESI) m / z: 832.7 (M+H) + .
[0157] 1 H NMR(400MHz, CDCl3)δ5.60(s,1H),5.39-5.31(m,4H),4.21-4.13(m,8H),2.78-2.75(m,2H),2.59-2.52(m,6H),2.46-2.42(m,1H),2. 32-2.28(m,2H),2.14-2.00(m,4H),1.82-1.80(m,2H),1.62-1.59(m,4H),1.48-1.26(m,42H),1.19-1.00(m,6H),0.90-0.80(m,9H).
[0158] Example 2: Preparation of ((3-hydroxypropyl)azanediyl)bis(hexane-6,1-diyl)(2E,2'E)-bis(3-propyltridec-2-enoate) (CPL-062-01)
[0159] Preparation of (E)-3-propyltridec-2-enoic acid 6-bromohexyl ester (Compound 2)
[0160] A mixture of compound 1 (514 mg, 2.02 mmol, 1.0 eq), 6-bromohexan-1-ol (438 mg, 2.42 mmol, 1.2 eq), TsOH-H2O (38 mg, 0.202 mmol, 0.1 eq) in toluene (8 mL) was stirred at 120°C for 16 hours. The mixture was concentrated and purified by chromatography on silica gel (PE: EA = 150: 1) to give compound 2 (674 mg, 80% yield) as a yellow oil.
[0161] 1 H NMR (400MHz, CDCL3) δ5.62(d,J=5.6Hz,1H),4.09(t,J=6.4Hz,2H),3.42(t,J=6.8Hz,2H),2.59-2.55(m,2H),2.1 4-2.09(m,2H),1.90-1.83(m,2H),1.69-1.62(m,2H),1.50-1.37(m,8H),1.29-1.26(m,14H),0.97-0.86(m,6H).
[0162] Preparation of ((3-hydroxypropyl)azanediyl)bis(hexane-6,1-diyl)(2E,2'E)-bis(3-propyltridec-2-enoate) (CPL-062-01)
[0163] A mixture of compound 2 (674 mg, 1.62 mmol, 2.2 eq), 3-aminopropan-1-ol (55 mg, 0.736 mmol, 1.0 eq), KCO (406 mg, 2.94 mmol, 4.0 eq) and NaI (44 mg, 0.294 mmol, 0.1 eq) in ACN (10 mL) was stirred at 80° C. for 16 h. The mixture was concentrated and purified by preparative HPLC to give the target CPL-062-01 (257 mg, 46.2% yield) as a colorless oil.
[0164] LCMS:LC / MS(ESI)m / z:748.23(M+H) + .
[0165] 1H NMR (400MHz, CDCL3) δ5.62 (d, J=5.2Hz, 1H 2H),4.08(t,J=6.4Hz,4H),3.83(t,J=5.2Hz,2H),3.20-3.05(m,2H),3.02-2.80(m,2H),2.59-2.55(m, 4H),2.14-2.10(m,4H),2.00-1.90(m,2H),1.69-1.62(m,6H),1.52-1.26(m,48H),0.96-0.86(m,12H).
[0166] Example 3: Preparation of ((3-hydroxypropyl)azanediyl)bis(hexane-6,1-diyl)(2E,2'E)-bis(3-pentylundecan-2-enoate) (CPL-069-01)
[0167] Preparation of (E)-3-pentylundec-2-enoic acid 6-bromohexyl ester (Compound 2)
[0168] Under nitrogen atmosphere, to a solution of (E)-3-pentylundec-2-enoic acid (600 mg, 2.4 mmol, 1.0 equiv) and 6-bromoheptan-1-ol (514 mg, 2.12 mmol, 1.2 equiv) in toluene (5 mL) was added TfOH.HO (50 mg, 0.264 mmol, 0.1 equiv). The reaction mixture was stirred at 120 ° C. for 16 hours. The solvent was removed under vacuum. The residue was purified by silica gel column (PE / EA=50 / 1) to give compound 2 (600 mg, 60% yield) as a colorless oil. LCMS: LC / MS (ESI) m / z: 417.14 (M+H) + .
[0169] 1H NMR(400MHz, CDCl3)δ5.61(s,1H),4.10-4.06(m,2H),3.46-3.40(m,2H),2.60-2.56(m,2H ),2.40-2.37(m,2H),2.18-2.10(m,2H),1.89-1.85(m,2H),1.68-1.55(m,2H),1.51-1.23 (m,21H),0.86-0.92(m,6H).
[0170] Preparation of ((3-hydroxypropyl)azanediyl)bis(hexane-6,1-diyl)(2E,2'E)-bis(3-pentyl undec-2-enoate)
[0171] To a solution of (Z)-7-bromoheptyl 3-propylhept-2-enoate (600 mg, 1.43 mmol, 2.1 equiv) and 3-aminopropan-1-ol (49 mg, 0.65 mmol, 1.0 equiv) in ACN (5 mL) was added KCO (360 mg, 2.535 mmol, 4.0 equiv) and NaI (49 mg, 0.33 mmol, 0.5 equiv) at 25°C, and the reaction mixture was stirred at 80°C for 20 hours. 30 mL of water was added to the mixture and extracted with EA (20 mL x 3). The organic layer was washed with aqueous NaCl (30 mL x 3), dried over NaSO, filtered, concentrated, and purified by preparative HPLC to give the target CPL-069-01 (127.1 mg, 7% yield) as a colorless oil. LCMS: LCMS (ESI) m / z: 748.23 (M+H) + .
[0172] 1H NMR(400MHz, CDCl3)δ5.61(s,2H),4.08-4.05(m,4H),3.81-3.72(m,2H),2.65-2.56( m,6H),2.42-2.39(m,4H),2.16-2.11(m,4H),1.62-1.27(m,54H),0.93-0.86(m,12H).
[0173] Example 4: Preparation of ((3-hydroxypropyl)azanediyl)di(heptane-7,1-diyl)(2E,2'E)-di(3-pentyltridec-2-enoate) (CPL-092-01)
[0174] Preparation of (E)-3-propyltridec-2-enoic acid 7-bromohexyl ester (Compound 2)
[0175] Under nitrogen atmosphere, to a solution of (E)-3-pentyl tridec-2-enoic acid (600 mg, 2.126 mmol, 1.0 equiv) and 7-bromoheptan-1-ol (412.5 mg, 2.126 mmol, 1.0 equiv) in toluene (10 mL) was added TfOH.HO (48.48 mg, 0.213 mmol, 0.1 equiv). The reaction mixture was stirred at 120 ° C for 16 hours. The solvent was removed under vacuum. The residue was passed through a silica gel column purification column (PE / EA=50 / 1) to give compound 2 (700 mg, 71.8% yield) as a colorless oil. LCMS: LC / MS (ESI) m / z: 459.28 (M+H) + .
[0176] 1H NMR (400 MHz, chloroform-d) δ 5.61 (s, 1H), 4.10-4.06 (m, 2H), 3.42-3.40 (m, 2H), 2.63-2.53 (m, 2H), 2.15-2.11 (m, 2H), 1.90-1.82 (m, 2H), 1.69-1.61 (m, 2H), 1.48-1.41 (m, 4H), 1.38-1.23 (m, 24H), 0.90-0.86 (m, 6H).
[0177] Preparation of ((3-hydroxypropyl)azanediyl)bis(heptane-7,1-diyl)(2E,2'E)-bis(3-pentyltridec-2-enoate) (CPL-092-01)
[0178] To a solution of (E)-7-bromoheptyl 3-pentyltridec-2-enoate (700 mg, 1.527 mmol, 2.1 equiv) and 3-aminopropan-1-ol (54.57 mg, 0.727 mmol, 1.0 equiv) in ACN (10 mL) was added KCO (401.30 mg, 2.908 mmol, 4.0 equiv) and NaI (54.41 mg, 0.363 mmol, 0.5 equiv) at 25° C. The reaction mixture was stirred at 80° C. for 20 hours. 30 mL of water was added to the mixture and extracted with EA (20 mL x 3). The organic layer was washed with aqueous NaCl (30 mL x 3) and dried over NaSO, filtered, concentrated, and purified by preparative HPLC to give the target CPL-092-01 (265.94 mg, 44.0% yield) as a colorless oil. LCMS: LCMS (ESI) m / z: 832.77 (M+H) + .
[0179] 1H NMR (400 MHz, chloroform-d) δ 5.61 (s, 2H), 4.08-4.05 (m, 4H), 3.81-3.78 (m, 2H), 2.64-2.41 (m, 10H), 2.14-2.10 (m, 4H), 1.68-1.62 (m, 6H), 1.50-1.26 (m, 60H), 0.91-0.86 (m, 12H).
[0180] Example 5: Preparation of ((3-hydroxypropyl)azanediyl)bis(octane-8,1-diyl)(2E,2'E)-bis(3-pentylundecan-2-enoate) (CPL-113-01)
[0181] Preparation of (E)-3-pentylundec-2-enoic acid 8-bromooctyl ester
[0182] To a solution of (E)-3-pentylundec-2-enoic acid (800 mg, 3.1 mmol, 1.0 equiv) and 6-bromoheptan-1-ol (774 mg, 3.7 mmol, 1.2 equiv) in toluene (5 mL) was added TfOH.HO (59 mg, 0.31 mmol, 0.1 equiv) under a nitrogen atmosphere. The reaction mixture was stirred at 120° C. for 16 hours. The solvent was removed under vacuum. The residue was purified by silica gel column (PE / EA=50 / 1) to give compound 2 (880 mg, 60% yield) as a colorless oil.
[0183] 1H NMR(400MHz, CDCl3)δ5.61(s,1H),4.09-4.05(m,2H),3.42-3.39(m,2H),2.60-2.56( m,2H),2.14-2.11(m,2H),1.89-1.60(m,2H),1.44-1.27(m,28H),0.91-0.86(m,6H).
[0184] Preparation of ((3-hydroxypropyl)azanediyl)bis(octane-8,1-diyl)(2E,2'E)-bis(3-propyltridec-2-enoate)
[0185] To a solution of (Z)-3-propylhept-2-enoic acid 7-bromoheptyl ester (880 mg, 1.97 mmol, 2.1 equiv) and 3-aminopropan-1-ol (68 mg, 0.9 mmol, 1.0 equiv) in ACN (5 mL) was added KCO (497 mg, 3.6 mmol, 4.0 equiv) and NaI (67 mg, 0.45 mmol, 0.5 equiv) at 25°C, and the reaction mixture was stirred at 80°C for 20 hours. 30 mL of water was added to the mixture and extracted with EA (20 mL x 3). The organic layer was washed with aqueous NaCl (30 mL x 3) and dried over NaSO, filtered, concentrated, and purified by preparative HPLC to give the target CPL-113-01 (101.27 mg, 5% yield) as a colorless oil. LCMS: LCMS (ESI) m / z: 804.34 (M+H) + .
[0186] 1H NMR (400MHz, CDCl3) δ5.61(s,2H),4.08-4.05(m,4H),3.81-3.78(m,2H),2.64-2.56 (m,6H),2.42-2.38(m,4H),2.14-2.11(m,4H),1.69-1.60(m,6H),1.46-1.21(m,56H),0.91-0.83(m,12H)
[0187] Example 6: Preparation of ((3-hydroxypropyl)azanediyl)bis(nonane-9,1-diyl)(2E,2'E)-bis(3-butyloct-2-enoate) (CPL-133-01)
[0188] Preparation of (E)-3-butyloctyl-2-enoic acid 9-bromononyl ester
[0189] A mixture of compound 1 (500 mg, 2.53 mmol, 1.0 eq), 9-bromononan-1-ol (840 mg, 3.78 mmol, 1.5 eq), TsOH-H2O (96 mg, 0.51 mmol, 0.2 eq) in toluene (10 mL) was stirred at 120°C for 16 hours. The mixture was concentrated and purified by chromatography on silica gel (PE: EA = 300: 1) to give compound 2 (720 mg, 70.8% yield) as a yellow oil.
[0190] 1 H NMR(400MHz, CDCl3)δ5.61(s,2H),4.08-4.05(m,2H),3.42-3.38(m,2H),2.60-2.56(m,2H),2. 15-2.11(m,2H),1.87-1.81(m,2H),1.65-1.62(m,2H),1.48-1.25(m,20H),0.93-0.87(m,6H).
[0191] Preparation of ((3-hydroxypropyl)azanediyl)bis(nonane-9,1-diyl)(2E,2'E)-bis(3-butyloct-2-enoate) (CPL-133-01)
[0192] A mixture of compound 2 (720 mg, 1.79 mmol, 2.4 eq), 3-aminopropan-1-ol (56 mg, 0.75 mmol, 1.0 eq), K CO (412 mg, 2.98 mmol, 4.0 eq) and NaI (23 mg, 0.15 mmol, 0.2 eq) in ACN (10 mL) was stirred at 80° C. for 16 h. The mixture was concentrated and purified by preparative HPLC to give the target CPL-133-01 (129 mg, 24% yield) as a colorless oil.
[0193] LCMS: LC / MS (ESI) m / z: 720.6 (M+H) + .
[0194] 1H NMR (400MHz, CDCl3) δ5.61(s,2H),4.08-4.03(m,4H),3.83-3.81(m,2H),3.03-2.93(m,2H),2.73-2.60( m,4H),2.59-2.56(m,4H),2.15-2.11(m,4H),2.01-1.86(m,2H),1.65-1.27(m,48H),0.96-0.82(m,12H).
[0195] Example 7: Preparation of ((3-hydroxypropyl)azanediyl)bis(undecane-11,1-diyl)(2E,2'E)-bis(3-butylnon-2-enoate) (CPL-174-01)
[0196] Preparation of (E)-3-butylnon-2-enoic acid 11-bromoundecyl ester (Compound 2)
[0197] Under nitrogen atmosphere, to a solution of (Z)-3-butylnon-2-enoic acid (500 mg, 2.356 mmol, 1.0 equiv) and 11-bromondecene-1-ol (589.21 mg, 2.356 mmol, 1.0 equiv) in toluene (10 mL) was added TfOH (44.85 mg, 0.236 mmol, 0.1 equiv). The reaction mixture was stirred at 120 ° C. for 16 hours. The solvent was removed under vacuum. The residue was purified by silica gel column (PE / EA=50 / 1) to give compound 2 (730 mg, 69.8% yield) as a colorless oil. LCMS: LC / MS (ESI) m / z: 445.26 (M+H) + .
[0198] 1H NMR (400 MHz, chloroform-d) δ 5.61 (s, 1H), 4.09-4.05 (m, 2H), 3.42-3.39 (m, 2H), 2.61-2.56 (m, 2H), 2.17-2.11 (m, 2H), 1.89-1.82 (m, 2H), 1.67-1.62 (m, 2H), 1.48-1.28 (m, 26H), 0.94-0.86 (m, 6H).
[0199] Preparation of ((3-hydroxypropyl)azanediyl)bis(undecane-11,1-diyl)(2E,2'E)-bis(3-butyloct-2-enoate) (CPL-174-01)
[0200] To a solution of (E)-3-butylnon-2-enoic acid 11-bromondecyl ester (730 mg, 1.643 mmol, 2.1 equiv) and 3-aminopropan-1-ol (58.70 mg, 0.782 mmol, 1.0 equiv) in ACN (10 mL) was added KCO (431.66 mg, 3.128 mmol, 4.0 equiv) and NaI (58.61 mg, 0.391 mmol, 0.5 equiv) at 25°C, and the reaction mixture was stirred at 80°C for 20 hours. 40 mL of water was added to the mixture and extracted with EA (30 mL x 3). The organic layer was washed with aqueous NaCl (40 mL x 3) and dried over NaSO, filtered, concentrated, and purified by preparative HPLC to give the target CPL-174-01 (181.92 mg, 28.9% yield) as a colorless oil. LCMS: LCMS (ESI) m / z: 804.74 (M+H) + .
[0201] 1H NMR(400MHz, CDCl3-d)δ5.61(s,2H),4.08-4.05(m,4H),3.81-3.79(m,2H),2.65-2.41( m,10H),2.15-2.11(m,4H),1.67-1.62(m,6H),1.46-1.27(m,56H),0.94-0.86(m,12H).
[0202] Example 8: Preparation of ((3-hydroxypropyl)azanediyl)bis(undecane-11,1-diyl)(2E,2'E)-bis(3-pentyltridec-2-enoate) (CPL-180-01)
[0203] Preparation of (Z)-3-propyltridec-2-enoic acid 11-bromondecyl ester (Compound 2)
[0204] Under a nitrogen atmosphere, to a solution of (Z)-3-pentyl tridec-2-enoic acid (600 mg, 1.569 mmol, 1.0 equiv) and 11-bromondecene-1-ol (392.39 mg, 1.569 mmol, 1.0 equiv) in toluene (5 mL) was added TfOH.HO (29.64 mg, 0.156 mmol, 0.1 equiv). The reaction mixture was stirred at 120 ° C for 16 hours. The solvent was removed under vacuum. The residue was purified by silica gel column (PE / EA=50 / 1) to give compound 2 (440 mg, 54.6% yield) as a colorless oil. LCMS: LC / MS (ESI) m / z: 515.34 (M+H) + .
[0205] 1H NMR(400MHz, CDCl3-d)δ5.61(s,1H),4.07(m,2H),3.40(m,2H),2.61-2.53(m,2H),2.1 2(m,2H),1.85(m,2H),1.63(m,2H),1.45(d,J=7.4Hz,4H),1.29(m,32H),0.89(m,6H).
[0206] Preparation of ((3-hydroxypropyl)azanediyl)bis(undecane-11,1-diyl)(2E,2'E)-bis(3-pentyltridec-2-enoate) (CPL-180-01)
[0207] To a solution of (Z)-3-pentyltridec-2-enoic acid 11-bromondecyl ester (440 mg, 0.855 mmol, 2.1 equiv) and 3-aminopropan-1-ol (30.55 mg, 0.407 mmol, 1.0 equiv) in ACN (5 mL) was added KCO (224.66 mg, 1.628 mmol, 4.0 equiv) and NaI (30.58 mg, 0.204 mmol, 0.5 equiv) at 25°C, and the reaction mixture was stirred at 80°C for 20 hours. 30 mL of water was added to the mixture and extracted with EA (20 mL x 3). The organic layer was washed with aqueous NaCl (30 mL x 3) and dried over NaSO, filtered, concentrated, and purified by preparative HPLC to give the target CPL-180-01 (194.57 mg, 50.6% yield) as a colorless oil. LCMS: LCMS (ESI) m / z: 944.89 (M+H) + .
[0208] 1H NMR(400MHz, CDCl3-d)δ5.61(s,2H),4.08-4.05(m,4H),3.82-3.81(m,2H),2.84-2.56(m,10H),2 .14-2.10(m,4H),1.80-1.61(m,6H),1.48-1.41(m,8H),1.38-1.23(m,68H),0.91-0.86(m,12H).
[0209] Example 9: Preparation of ((2-hydroxyethyl)azanediyl)bis(octane-8,1-diyl)(2E,2'E)-bis(3-butylnon-2-enoate) (CPL-455-01)
[0210] Preparation of 8-bromooctyl 3-butylhept-2-enoate (Compound 2)
[0211] A mixture of compound 1 (1.5 g, 7.07 mmol, 1.0 eq), 8-bromooctan-1-ol (1.77 g, 8.48 mmol, 1.2 eq) and TsOH-H2O (135 mg, 0.707 mmol, 0.1 eq) in toluene (30 mL) was stirred at 120° C. under a nitrogen atmosphere for 16 hours. The mixture was concentrated and purified by silica gel column to give compound 2 (2.69 g, 94.7% yield) as a colorless oil.
[0212] 1 H NMR (400MHz, CDCL3) δ5.61(s,1H),4.08-4.04(m,2H),3.42-3.39(m,2H),2.60-2.56(m,2H),2. 18-2.11(m,2H),1.89-1.82(m,2H),1.67-1.60(m,2H),1.46-1.27(m,20H),0.93-0.87(m,6H).
[0213] Preparation of ((2-hydroxyethyl)azanediyl)bis(octane-8,1-diyl)(2E,2'E)-bis(3-butylnon-2-enoate) (CPL-455-01)
[0214] A mixture of compound 2 (906 mg, 2.248 mmol, 2.2 eq), 2-aminoethan-1-ol (62 mg, 1.022 mmol, 1.0 eq), KCO (564 mg, 4.088 mmol, 4.0 eq) and NaI (15 mg, 0.1022 mmol, 0.1 eq) in ACN (15 mL) was stirred at 80° C. for 16 h. The mixture was concentrated and purified by preparative HPLC to give the target CPL-455-01 (322 mg, 44.6% yield) as a colorless oil.
[0215] LCMS: LC / MS (ESI) m / z: 706.7 (M+H) + .
[0216] 1 H NMR(400MHz, CDCl3)δ5.61(s,2H),4.08-4.03(m,4H),3.90-3.80(m,2H),3.05-2.87(m,6H),2. 60-2.56(m,4H),2.15-2.11(m,4H),1.70-1.60(m,4H),1.46-1.27(m,44H),0.93-0.86(m,12H).
[0217] Example 10: Preparation of ((3-hydroxypropyl)azanediyl)bis(octane-8,1-diyl)(2E,2'E)-bis(3-butylnon-2-enoate) (CPL-456-01)
[0218] Preparation of ((3-hydroxypropyl)azanediyl)bis(octane-8,1-diyl)(2E,2'E)-bis(3-butyloct-2-enoate) (CPL-456-01)
[0219] A mixture of compound 1 (903 mg, 2.24 mmol, 2.2 eq), 3-aminopropan-1-ol (76 mg, 1.02 mmol, 1.0 eq), KCO (562 mg, 4.07 mmol, 4.0 eq) and NaI (15 mg, 0.10 mmol, 0.1 eq) in ACN (15 mL) was stirred at 80° C. for 16 h. The mixture was concentrated and purified by preparative HPLC to give the target CPL-456-01 (351 mg, 47.8% yield) as a colorless oil.
[0220] LCMS: LC / MS (ESI) m / z: 720.0 (M+H) + .
[0221] 1 H NMR (400MHz, CDCL3) δ5.61(s,2H),4.08-4.03(m,4H),3.83-3.80(m,2H),3.03-2.85(m,2H),2.88-2.65(m,2H),2. 60-2.56(m,4H),2.15-2.11(m,4H),1.95-1.80(m,2H),1.72-1.55(m,6H),1.46-1.27(m,44H),0.93-0.86(m,12H).
[0222] Example 11: Preparation of ((4-hydroxybutyl)azanediyl)bis(octane-8,1-diyl)(2E,2'E)-bis(3-butylnon-2-enoate) (CPL-457-01)
[0223] Preparation of ((4-hydroxybutyl)azanediyl)bis(octane-8,1-diyl)(2E,2'E)-bis(3-butylnon-2-enoate) (CPL-457)
[0224] A mixture of compound 1 (881 mg, 2.186 mmol, 2.2 eq), 4-aminobutan-1-ol (88 mg, 0.994 mmol, 1.0 eq), KCO (548 mg, 3.976 mmol, 4.0 eq) and NaI (15 mg, 0.0994 mmol, 0.1 eq) in ACN (15 mL) was stirred at 80° C. for 16 h. The mixture was concentrated and purified by preparative HPLC to give the target CPL-457-01 (334 mg, 45.8% yield) as a colorless oil.
[0225] LCMS: LC / MS (ESI) m / z: 734.7 (M+H) + .
[0226] 1 H NMR(400MHz, CDCl3)δ5.61(s,2H),4.08-4.03(m,4H),3.73-3.70(m,2H),3.03-2.87(m,4H),2.60-2.56( m,4H),2.15-2.12(m,4H),2.00-1.93(m,2H),1.72-1.62(m,6H),1.46-1.28(m,46H),0.93-0.86(m,12H).
[0227] Example 12: Preparation of pentyl 5-((2-hydroxyethyl)(6-((3-octylundec-2-enoyl)oxy)hexyl)amino)dodecanoate (CPL-002)
[0228] A mixture of 5-bromopentyl dodecanoate (131 mg, 0376 mmol, 1.1 eq), 6-(2-hydroxyethylamino)-hexyl-3-octyl undecyl-2-enoate (150 mg, 0.342 mmol, 1.0 eq), KCO (47 mg, 0.342 mmol, 1 eq), CsCO (33 mg, 0.1026 mmol, 0.3 eq) and NaI (15 mg, 0.1026 mmol, 0.3 eq) in ACN (6 mL) was stirred at 85° C. for 16 hours. 40 mL of water was added and the mixture was extracted three times with 20 mL of ethyl acetate. The organic phase was washed three times with 40 mL of sodium chloride solution, filtered and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to obtain the target CPL-002 (60 mg, 25% yield) as a colorless oil.
[0229] LCMS: LC / MS (ESI) m / z: 708.7 (M+H) + .
[0230] 1HNMR (400MHz, CDCl3) δ5.54(s,1H),3.97-4.01(m,4H),3.50-3.53(m,2H),2.56-2.59(m,2H),2.54–2.39(m,6H),2.22(t,J=7.5Hz,2H),2 .09–2.00(m,2H),1.53-1.61(m,6H),1.48–1.42(m,3H),1.40–1.34(m,4H),1.33–1.28(m,4H),1.20(d,J=10.3Hz,40H),0.79-0.82(m,9H).
[0231] Example 13: Preparation of ((4-hydroxybutyl)azepinediyl)bis(pentane-5,1-diyl)(2E,2'E)-bis(3-hexylundec-2-enoate) (CPL-003)
[0232] A mixture of (E)-5-bromopentyl-3-hexyl undec-2-enoate (50 mg, 0.12 mmol, 1.0 equiv), 4-amino-1-butanol (5.34 mg, 0.06 mmol, 0.3 equiv), KCO (49.68 mg, 0.36 mmol, 3.0 equiv), and NaI (5.4 mg, 0.036 mmol, 0.3 equiv) in ACN (1 mL) was stirred at 80° C. for 24 hours. 30 mL of water was added and the mixture was extracted three times with 20 mL of ethyl acetate. The organic phase was washed three times with 30 mL of sodium chloride solution, filtered, and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to give the target CPL-003 (28.81 mg, 30.7% yield) as a colorless oil.
[0233] LCMS: LCMS (ESI) m / z: 762.69 (M+H) + .
[0234] 1H NMR(400MHz,Chloroform-d)δ5.61(s,1H),4.07(q,J=6.2Hz,4H),3.73–3.65(m,2H) ,3.00(d,J=23.7Hz,2H),2.90(d,J=13.6Hz,4H),2.58(m,3H),2.13(t,J=7.7Hz,3H), 2.06–2.00(m,2H),1.92–1.85(m,2H),1.83–1.74(m,4H),1.69(d,J=6.9Hz,4H),1.43(m,11H),1.29(m,36H),0.89(m,12H).
[0235] Example 14: Preparation of ((3-hydroxypropyl)azepinediyl)bis(butane-4,1-diyl)(2E,2'E)-bis(3-butylundec-2-enoate) (CPL-021)
[0236] A mixture of (E)-4-bromobutanyl-3-butanyl undec-2-enoate (286 mg, 0.762 mmol, 2.4 eq), 3-amino-1-propanol (24 mg, 0.317 mmol, 1.0 eq), KCO (175 mg, 1.268 mmol, 4.0 eq) and NaI (24 mg, 0.159 mmol, 0.5 eq) in ACN (15 mL) was stirred at 80° C. for 40 h. The mixture was concentrated and purified by preparative HPLC to give the target CPL-021 (49 mg, 23.1% yield) as a colorless oil.
[0237] LCMS:LC / MS(ESI)m / z:663.58(M+H) +
[0238] 1H NMR (400MHz, CDCL3) δ5.62(s,1H),4.10-4.06(m,4H),3.81-3.78(m,2H),2.65-2.56(m,6H),2. 48-2.44(m,4H),2.15-2.10(m,4H),1.70-1.54(m,6H),1.50-1.19(m,37H),0.93-0.87(m,12H).
[0239] Example 15: Preparation of ((3-hydroxypropyl)azepinediyl)bis(butane-4,1-diyl)(2E,2'E)-bis(2-ylidenehexyldecanoate) (CPL-025)
[0240] A mixture of (E)-4-bromobutanyl-3-pentyl undec-2-enoate (300 mg, 0.77 mmol, 2.2 equiv), 3-amino-1-propanol (24.19 mg, 0.32 mmol, 1.0 equiv), KCO (89.02 mg, 0.64 mmol, 2.0 equiv) and NaI (9.65 mg, 0.06 mmol, 0.2 equiv) in DMF (5 mL) was stirred at 80° C. for 48 h. The mixture was concentrated and purified by preparative HPLC to give the target CPL-025 (66.75 mg, 29.93% yield) as a colorless oil.
[0241] LCMS:LC / MS(ESI)m / z:892.16(M+H) + .
[0242] 1H NMR (400MHz, CDCl3) δ5.62 (s, 2H), 4.08 (s, 4H), 3.79 (s, 2H), 2.64 (d, J = 3.7 Hz,2H),2.58(s,4H),2.45(s,4H),2.13(s,4H),1.25(s,46H),0.88(s,12H).
[0243] Example 16: Preparation of ((3-hydroxypropyl)azadiyl)bis(butane-4,1-diyl)(2Z,2'Z)-bis(3-pentyltridecyl-2-enoate) (CPL-026)
[0244] A mixture of (Z)-4-bromobutanyl-3-pentyl tridec-2-enoate (410 mg, 0.985 mmol, 2.1 equiv), 3-amino-1-propanol (35.78 mg, 0.47 mmol, 1.0 equiv), KCO (259.44 mg, 1.88 mmol, 4.0 equiv) and NaI (35.22 mg, 0.235 mmol, 0.5 equiv) in ACN (5 mL) was stirred at 80° C. for 20 hours. 30 mL of water was added and the mixture was extracted three times with 20 mL of ethyl acetate. The organic phase was washed three times with 30 mL of sodium chloride solution, filtered and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to give the target CPL-026 (111.03 mg, 31.6% yield) as a colorless oil.
[0245] LCMS: LCMS (ESI) m / z: 748.67 (M+H) + .
[0246] 1H NMR(400MHz,Chloroform-d)δ5.61(d,J=1.3Hz,2H),4.08(t,J=6.3Hz,4H),3.79(t,J=5.2Hz,2H),2.65(s,2H),2.61–2.55(m,4H ),2.46(s,4H),2.13(m,4H),1.66(m,4H),1.57(d,J=7.0Hz,4H),1.44(t,J=7.1Hz,6H),1.35–1.23(m,40H),0.90–0.86(m,12H).
[0247] Example 17: Preparation of ((3-hydroxypropyl)azepinediyl)bis(butane-4,1-diyl)(2E,2'E)-bis(3-hexyldecan-2-enoate) (CPL-031)
[0248] A mixture of (Z)-4-bromobutanyl-3-hexyldec-2-enoate (180 mg, 0.4 mmol, 2.1 equiv), 3-amino-1-propanol (15 mg, 0.23 mmol, 1.0 equiv), KCO (110.5 mg, 0.8 mmol, 4.0 equiv) and NaI (15 mg, 0.1 mmol, 0.5 equiv) in ACN (5 mL) was stirred at 80° C. for 20 hours. 30 mL of water was added and the mixture was extracted three times with 20 mL of ethyl acetate. The organic phase was washed three times with 30 mL of sodium chloride solution, filtered and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to give the target CPL-031 (49.42 mg, 9% yield) as a colorless oil.
[0249] LCMS (ESI) m / z: 692.12 (M+H) + .
[0250] 1H NMR (400MHz, CDCl3) δ5.61 (s, 2H), 4.09 (t, J = 6.4Hz, 4H), 3.84–3.73 (m, 2H), 2.72–2.54 (m, 6H),2.46(s,4H),2.15–2.08(m,4H),1.65(s,4H),1.31–1.24(m,42H),0.94-0.87(m,12H).
[0251] Example 18: Preparation of ((3-hydroxypropyl)azepinediyl)bis(butane-4,1-diyl)(2Z,2'Z)-bis(3-heptylundec-2-enoate) (CPL-032)
[0252] A mixture of (Z)-4-bromobutanyl-3-heptyl undec-2-enoate (230 mg, 0.553 mmol, 2.1 equiv), 3-amino-1-propanol (19.74 mg, 0.236 mmol, 1.0 equiv), KCO (145.59 mg, 1.052 mmol, 4.0 equiv) and NaI (19.59 mg, 0.131 mmol, 0.5 equiv) in ACN (5 mL) was stirred at 80° C. for 20 hours. 30 mL of water was added and the mixture was extracted three times with 20 mL of ethyl acetate. The organic phase was washed three times with 30 mL of sodium chloride solution, filtered and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to give the target CPL-032 (79.86 mg, 40.6% yield) as a colorless oil.
[0253] LCMS (ESI) m / z: 748.67 (M+H) + .
[0254] 1H NMR(400MHz,Chloroform-d)δ5.61(s,2H),4.13–4.06(m,4H),3.81(t,J=5.3Hz,2H),3.18– 2.41(m,10H),2.18–2.09(m,4H),1.58–1.42(m,10H),1.29(t,J=6.7Hz,44H),0.88(m,12H).
[0255] Example 19: Preparation of ((3-hydroxypropyl)azadiyl)bis(pentane-5,1-diyl)(2E,2'E)-bis(3-propylundec-2-enoate) (CPL-039)
[0256] A mixture of (E)-5-bromopentyl-3-propanyl undec-2-enoate (313 mg, 0.834 mmol, 2.4 eq), 3-amino-1-propanol (26 mg, 0.347 mmol, 1.0 eq), KCO (191 mg, 1.388 mmol, 4.0 eq) and NaI (5.2 mg, 0.0347 mmol, 0.1 eq) in ACN (8 mL) was stirred at 80° C. for 16 h. The mixture was concentrated and purified by preparative HPLC to give the target CPL-039 (72 mg, 31.3% yield) as a colorless oil.
[0257] LCMS: LC / MS (ESI) m / z: 664.5 (M+H) + .
[0258] 1H NMR (400MHz, CDCL3) δ5.62(d,J=5.2Hz,2H),4.09(t,J=6.8Hz,4H),3.80(t,J=5.2Hz,2H),2.64(t,J=5.2Hz,2H),2.59-2.55( m,4H),2.44-2.40(m,4H),2.14-2.09(m,4H),1.70-1.62(m,6H),1.54-1.41(m,10H),1.37-1.26(m,26H),0.96-0.86(m,12H).
[0259] Example 20: Preparation of ((3-hydroxypropyl)azadiyl)bis(pentane-5,1-diyl)(2E,2'E)-bis(3-butylundec-2-enoate) (CPL-043)
[0260] A mixture of (E)-5-bromopentyl-3-butyl undec-2-enoate (379 mg, 0.973 mmol, 2.4 eq), 3-amino-1-propanol (30 mg, 0.406 mmol, 1.0 eq), KCO (224 mg, 1.624 mmol, 4.0 eq) and NaI (30 mg, 0.203 mmol, 0.5 eq) in ACN (4 mL) was stirred at 80° C. for 40 h. The mixture was concentrated and purified by preparative HPLC to give the target CPL-043 (99 mg, 35.9% yield) as a colorless oil.
[0261] LCMS:LC / MS(ESI)m / z:691.61(M+H) + .
[0262] 1H NMR (400MHz, CDCL3) δ5.62(s,1H),4.09-4.06(m,4H),3.80-3.78(m,2H),2.66-2.56 (m,6H),2.44-2.41(m,4H),2.15-2.12(m,4H),1.79-1.63(m,6H),1.56-1.19(m,41H),0.96-0.83(m,12H).
[0263] Example 21: Preparation of ((3-hydroxypropyl)azadiyl)bis(pentane-5,1-diyl)(2E,2'E)-bis(3-butyltridec-2-enoate) (CPL-044)
[0264] A mixture of (E)-5-bromopentyl-3-butyl dodec-2-enoate (350 mg, 0.838 mmol, 2.4 eq), 3-amino-1-propanol (26 mg, 0.349 mmol, 1.0 eq), KCO (193 mg, 1.397 mmol, 4.0 eq) and NaI (26 mg, 0.175 mmol, 0.5 eq) in ACN (4 mL) was stirred at 80° C. for 40 h. The mixture was concentrated and purified by preparative HPLC to give the target CPL-044 (94.27 mg, 36.1% yield) as a colorless oil.
[0265] LCMS:LC / MS(ESI)m / z:747.67(M+H) + .
[0266] 1H NMR (400MHz, CDCL3) δ5.61(s,2H),4.09-4.05(m,4H),3.80-3.77(m,2H),2.64-2.63(m,2H),2.58-2.53( m,4H),2.52-2.43(m,4H),2.13-2.04(m,4H),1.68-1.65(m,6H),1.35-1.26(m,49H),0.93-0.79(m,12H).
[0267] Example 22: Preparation of ((3-hydroxypropyl)azepinediyl)bis(hexane-6,1-diyl)(2E,2'E)-bis(3-pentylundec-2-enoate) (CPL-047)
[0268] A mixture of (E)-5-bromopentyl-3-pentyl undecyl-2-enoate (570 mg, 1.4 mmol, 2.2 equiv), 3-amino-1-propanol (45 mg, 0.6 mmol, 1.0 equiv), KCO (333 mg, 1.31 mmol, 2 equiv) and NaI (44 mg, 0.02 mmol, 0.2 equiv) in DMF (5 mL) was stirred at 80° C. for 40 h. The mixture was concentrated and purified by preparative HPLC to give the target CPL-047 (23.12 mg, 2% yield) as a colorless oil.
[0269] LCMS: LC / MS (ESI) m / z: 720.1 (M+H) + .
[0270] 1H NMR (400MHz, CDCl3) δ5.61(s,2H),4.08(t,J=6.4Hz,4H),3.78(d,J=5.5Hz,3H),3.21(s,2H),3.03(s,4H) ,2.66–2.56(m,4H),2.20–2.10(m,4H),1.99(d,J=35.8Hz,4H),1.62–1.25(m,143H),0.90–0.88(m,12H).
[0271] Example 23: Preparation of ((3-hydroxypropyl)azadiyl)bis(pentane-5,1-diyl)(2E,2'E)-bis(3-pentyltridecyl-2-enoate) (CPL-048)
[0272] A mixture of (E)-5-bromopentyl-3-pentyl tridec-2-enoate (210 mg, 0.488 mmol, 2.1 equiv), 3-amino-1-propanol (17.44 mg, 0.232 mmol, 1.0 equiv), KCO (325.82 mg, 0.928 mmol, 4.0 equiv) and NaI (17.38 mg, 0.116 mmol, 0.5 equiv) in ACN (5 mL) was stirred at 80° C. for 20 hours. 30 mL of water was added and the mixture was extracted three times with 20 mL of ethyl acetate. The organic phase was washed three times with 30 mL of sodium chloride solution, filtered and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to give the target CPL-048 (67.42 mg, 37.4% yield) as a colorless oil.
[0273] LCMS (ESI) m / z: 776.71 (M+H) + .
[0274] 1H NMR(400MHz,Chloroform-d)δ5.61(s,2H),4.07(t,J=6.7Hz,4H),3.79(t,J=5.1Hz,2H),2.64(s,2H),2.60–2.53(m, 4H),2.46–2.38(m,4H),2.16–2.09(m,4H),1.66(s,4H),1.49–1.39(m,10H),1.35–1.23(m,44H),0.90–0.86(m,12H).
[0275] Example 24: Preparation of ((3-hydroxypropyl)azadiyl)bis(pentane-5,1-diyl)(2E,2'E)-bis(3-hexylnon-2-enoate) (CPL-049)
[0276] A mixture of (E)-6-bromopentyl-3-hexylnon-2-enoate (480 mg, 1.24 mmol, 2.4 equiv), 3-amino-1-propanol (39 mg, 0.51 mmol, 1.0 equiv), KCO (285 mg, 2.06 mmol, 4.0 equiv) and NaI (9 mg, 0.1 mmol, 0.2 equiv) in ACN (10 mL) was stirred at 80° C. for 16 h. The mixture was concentrated and purified by preparative HPLC to give the target CPL-049 (78 mg, 21% yield) as a colorless oil.
[0277] LC / MS (ESI) m / z: 692.7 (M+H) + .
[0278] 1H NMR(400MHz, CDCl3)δ5.61(s,2H),4.17–4.00(m,4H),3.94–3.60(m,2H),3.11–2.85(m,2H),2.86–2.62( m,4H),2.62–2.51(m,4H),2.20–2.09(m,4H),1.94–1.79(m,2H),1.73–1.33(m,26H),0.97–0.81(m,12H).
[0279] Example 25: Preparation of ((3-hydroxypropyl)azadiyl)bis(pentane-5,1-diyl)(2E,2'E)-bis(3-butyldec-2-enoate) (CPL-052)
[0280] A mixture of (E)-5-bromopentyl-3-butyldec-2-enoate (420 mg, 1.12 mmol, 2.1 equiv), 3-amino-1-propanol (38.2 mg, 0.48 mmol, 1.0 equiv), KCO (280.6 mg, 1.9 mmol, 4.0 equiv) and NaI (45 mg, 0.24 mmol, 0.5 equiv) in ACN (5 mL) was stirred at 80° C. for 20 hours. 30 mL of water was added and the mixture was extracted three times with 20 mL of ethyl acetate. The organic phase was washed three times with 30 mL of sodium chloride solution, filtered and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to give the target CPL-052 (93.01 mg, 12% yield) as a colorless oil.
[0281] LCMS (ESI) m / z: 664 (M+H) + .
[0282] 1H NMR(400MHz, CDCl3)δ5.61(s,2H),4.07(t,J=6.8Hz,4H),3.86–3.74(m,2H),2.69–2.52( m,6H),2.45–2.36(m,4H),2.12(d,J=6.8Hz,4H),1.52–1.24(m,22H),0.94–0.87(m,12H).
[0283] Example 26: Preparation of ((3-hydroxypropyl)azadiyl)bis(hexane-6,1-diyl)(2E,2'E)-bis(3-propylundec-2-enoate) (CPL-061)
[0284] A mixture of (E)-6-bromohexyl-3-propanyl undec-2-enoate (440 mg, 1.13 mmol, 2.4 equiv), 3-amino-1-propanol (35 mg, 0.47 mmol, 1.0 equiv), KCO (259 mg, 1.88 mmol, 4.0 equiv) and NaI (7 mg, 0.047 mmol, 0.1 equiv) in ACN (6 mL) was stirred at 80° C. for 16 h. The mixture was concentrated and purified by preparative HPLC to give the target CPL-061 (105 mg, 32.3% yield) as a colorless oil.
[0285] LCMS: LC / MS (ESI) m / z: 692.6 (M+H) + .
[0286] 1H NMR (400MHz, CDCL3) δ5.62(d,J=5.2Hz,2H),4.08(t,J=6.8Hz,4H),3.80(t,J=5.2Hz,2H),2.64(t,J=5.2Hz,2H),2. 59-2.55(m,4H),2.41-2.38(m,4H),2.14-2.09(m,4H),1.69-1.61(m,6H),1.52-1.27(m,40H),0.96-0.86(m,12H).
[0287] Example 27: Preparation of ((3-hydroxypropyl)azepinediyl)bis(hexane-6,1-diyl)(2E,2'E)-bis(3-butylundec-2-enoate) (CPL-065)
[0288] A mixture of (E)-6-bromohexyl-3-butyl undec-2-enoate (401 mg, 0.997 mmol, 2.4 eq), 3-amino-1-propanol (31 mg, 0.415 mmol, 1.0 eq), KCO (229 mg, 1.66 mmol, 4.0 eq) and NaI (31 mg, 0.208 mmol, 0.5 eq) in ACN (4 mL) was stirred at 80° C. for 40 h. The mixture was concentrated and purified by preparative HPLC to give the target CPL-065 (102 mg, 34.3% yield) as a colorless oil.
[0289] LCMS:LC / MS(ESI)m / z:719.64(M+H) + .
[0290] 1H NMR (400MHz, CDCL3) δ5.61(s,1H),4..08-4.05(m,4H),3.81-3.78(m,2H),2.64-2.56(m,6H),2. 43-2.39(m,4H),2.15-2.11(m,4H),1.69-1.61(m,6H),1.50-1.19(m,45H),0.94-0.87(m,12H).
[0291] Example 28: Preparation of ((3-hydroxypropyl)azadiyl)bis(hexane-6,1-diyl)(2E,2'E)-bis(3-butyl-2-tridecenoate) (CPL-066)
[0292] A mixture of (E)-6-bromohexyl-3-butyl tridec-2-enoate (408 mg, 0.946 mmol, 2.4 eq), 3-amino-1-propanol (30 mg, 0.394 mmol, 1.0 eq), KCO (218 mg, 1.576 mmol, 4.0 eq) and NaI (30 mg, 0.197 mmol, 0.5 eq) in ACN (4 mL) was stirred at 80° C. for 40 h. The mixture was concentrated and purified by preparative HPLC to give the target CPL-066 (126.09 mg, 41.22% yield) as a colorless oil.
[0293] LCMS:LC / MS(ESI)m / z:776.29(M+H) + .
[0294] 1H NMR (400MHz, CDCL3) δ5.61(s,2H),4.09-4.05(m,4H),3.80-3.77(m,2H),2.64-2.63(m,2H),2.58-2.53( m,4H),2.52-2.43(m,4H),2.13-2.04(m,4H),1.68-1.65(m,6H),1.35-1.26(m,53H),0.93-0.79(m,12H).
[0295] Example 29: Preparation of ((3-hydroxypropyl)azadiyl)bis(hexane-6,1-diyl)(2Z,2'Z)-bis(3-pentyltridecyl-2-enoate) (CPL-070)
[0296] A mixture of (E)-6-bromohexyl-3-pentyl tridec-2-enoate (430 mg, 0.968 mmol, 2.1 equiv), 3-amino-1-propanol (34.57 mg, 0.461 mmol, 1.0 equiv), KCO (254.47 mg, 1.84 mmol, 4.0 equiv) and NaI (34.5 mg, 0.230 mmol, 0.5 equiv) in ACN (5 mL) was stirred at 80° C. for 20 hours. 30 mL of water was added and the mixture was extracted three times with 20 mL of ethyl acetate. The organic phase was washed three times with 30 mL of sodium chloride solution, filtered and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to give the target CPL-070 (90.91 mg, 24.32% yield) as a colorless oil.
[0297] LCMS (ESI) m / z: 804.74 (M+H) + .
[0298] 1H NMR(400MHz,Chloroform-d)δ5.61(s,2H),4.07(t,J=6.7Hz,4H),3.79(t,J=5.1Hz,2H),2.64(s,2H),2.61–2.54(m,4H),2 .41(d,J=8.6Hz,4H),2.12(t,J=7.7Hz,4H),1.64(d,J=7.7Hz,4H),1.46–1.37(m,10H),1.34–1.22(m,48H),0.89(m,12H).
[0299] Example 30: Preparation of ((3-hydroxypropyl)azadiyl)bis(hexane-6,1-diyl)(2E,2'E)-bis(3-hexylnon-2-enoate) (CPL-071)
[0300] A mixture of (E)-6-bromohexyl-3-hexylnon-2-enoate (400 mg, 0.99 mmol, 2.4 equiv), 3-amino-1-propanol (31 mg, 0.41 mmol, 1.0 equiv), KCO (229 mg, 1.576 mmol, 4.0 equiv) and NaI (13 mg, 0.08 mmol, 0.2 equiv) in ACN (10 mL) was stirred at 80° C. for 16 h. The mixture was concentrated and purified by preparative HPLC to give the target CPL-071 (101 mg, 34% yield) as a colorless oil.
[0301] LC / MS (ESI) m / z: 720.7 (M+H) + .
[0302] 1H NMR (400MHz, CDCl3) δ5.61(s,2H),4.19–3.97(m,4H),3.93–3.71(m,2H),3.04–2.87(m,2H),2.85–2.64( m,4H),2.64–2.49(m,4H),2.20–2.08(m,4H),1.92–1.79(m,2H),1.77–1.35(m,48H),0.97–0.78(m,12H).
[0303] Example 31: Preparation of ((3-hydroxypropyl)azadiylbis(hexane-6,1-diyl)(2E,2'E)-bis(3-butyldec-2-enoate) (CPL-074)
[0304] A mixture of (E)-6-bromohexyl-3-butyldec-2-enoate (387 mg, 0.95 mmol, 2.1 equiv), 3-amino-1-propanol (36 mg, 0.48 mmol, 1.0 equiv), KCO (263 mg, 1.9 mmol, 4.0 equiv), and NaI (36 mg, 0.24 mmol, 0.5 equiv) in ACN (5 mL) was stirred at 80° C. for 20 hours. 30 mL of water was added, and the mixture was extracted three times with 20 mL of ethyl acetate. The organic phase was washed three times with 30 mL of sodium chloride solution, filtered, and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to afford the target CPL-074 (86.55 mg, 13% yield) as a colorless oil.
[0305] LCMS: LCMS (ESI) m / z: 692.12 (M+H) + .
[0306] 1H NMR(400MHz, CDCl3)δ5.61(s,2H),4.07(t,J=6.7Hz,4H),3.86–3.74(m,2H),2.69–2.52( m,6H),2.45–2.36(m,4H),2.12(d,J=6.8Hz,4H),1.52–1.24(m,51H),0.94–0.87(m,12H).
[0307] Example 32: Preparation of ((3-hydroxypropyl)azadiyl)bis(hexane-6,1-diyl)(2E,2'E)-bis(3-octyltridecyl-2-enoate) (CPL-079)
[0308] A mixture of (E)-6-bromohexyl-3-octyl tridec-2-enoate (420 mg, 0.8642 mmol, 2.3 equiv), 3-amino-1-propanol (28 mg, 0.3757 mmol, 1.0 equiv), KCO (156 mg, 1.1271 mmol, 3.0 equiv) and CsCO (61 mg, 0.1879 mmol, 0.5 equiv) in ACN (8 mL) was stirred at 90° C. for 24 hours. 40 mL of water was added and the mixture was extracted three times with 20 mL of ethyl acetate. The organic phase was washed three times with 40 mL of sodium chloride solution, filtered and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to give the target CPL-079 (76.07 mg, 10% yield) as a colorless oil.
[0309] LCMS: LC / MS (ESI) m / z: 888.9 (M+H) + .
[0310] 1HNMR (400MHz, CDCl3) δ5.54(s,2H),4.00(t,J=6.7Hz,4H),3.71(dd,J=10.5,5.4Hz,2H),2.52(dd,J=19.0,11.4Hz,6H),2.34(s,2H) ,2.10–2.02(m,4H),1.98–1.93(m,1H),1.59(dd,J=13.9,7.0Hz,6H),1.40–1.36(m,6H),1.19(s,64H),0.81(dd,J=6.9,5.6Hz,12H).
[0311] Example 33: Preparation of ((3-hydroxypropyl)azepinediyl)bis(heptane-7,1-diyl)(2E,2'E)-bis(3-pentylnon-2-enoate) (CPL-090)
[0312] A mixture of (E)-6-bromoheptanyl-3-pentanylnon-2-enoate (565 mg, 1.4055 mmol, 2.3 equiv), 3-amino-1-propanol (45 mg, 0.6111 mmol, 1.0 equiv), KCO (253 mg, 1.833 mmol, 3.0 equiv), CsCO (99 mg, 0.3056 mmol, 0.5 equiv), and NaI (45 mg, 0.3056 mmol, 0.5 equiv) in ACN (8 mL) was stirred at 80° C. for 48 hours. 40 mL of water was added and the mixture was extracted three times with 20 mL of ethyl acetate. The organic phase was washed three times with 40 mL of sodium chloride solution, filtered, and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to give the target CPL-090 (148.8 mg, 15% yield) as a colorless oil.
[0313] LCMS: LC / MS (ESI) m / z: 720.7 (M+H) + .
[0314] 1HNMR(400MHz, CDCl3)δ5.54(s,2H),4.00(t,J=6.7Hz,4H),3.75–3.70(m,2H),2.52(dd,J=20.2,12.6Hz,6H),2.41–2.27(m,4H), 2.10–2.02(m,4H),1.58(dd,J=13.9,7.2Hz,6H),1.38(d,J=7.0Hz,8H),1.23(ddd,J=18.4,10.2,5.8Hz,36H),0.84–0.80(m,12H).
[0315] Example 34: Preparation of ((3-hydroxypropyl)azepinediyl)bis(heptane-7,1-diyl)(2E,2'E)-bis(3-butyldec-2-enoate) (CPL-096)
[0316] A mixture of (E)-6-bromoheptanyl-3-butanyldec-2-enoate (421 mg, 0.95 mmol, 2.1 equiv), 3-amino-1-propanol (33 mg, 0.44 mmol, 1.0 equiv), KCO (235 mg, 1.7 mmol, 4.0 equiv), and NaI (32 mg, 0.22 mmol, 0.5 equiv) in ACN (5 mL) was stirred at 80° C. for 20 hours. 30 mL of water was added, and the mixture was extracted three times with 20 mL of ethyl acetate. The organic phase was washed three times with 30 mL of sodium chloride solution, filtered, and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to give the target CPL-096 (101.27 mg, 5% yield) as a colorless oil.
[0317] LCMS: LCMS (ESI) m / z: 720.18 (M+H) + .
[0318] 1H NMR (400MHz, CDCl3) δ5.63 (d, J = 9.3Hz, 2H), 4.07 (s, 4H), 3.81 (s, 2H), 2.59 (s,8H),2.41(s,5H),2.13(s,6H),1.66(s,10H),1.28(s,50H),0.90(s,12H)
[0319] Example 35: Preparation of ((3-hydroxypropyl)azepinediyl)bis(heptane-7,1-diyl)(2Z,2'Z)-bis(3-octyltridecane-2-enoate) (CPL-101)
[0320] A mixture of (Z)-6-bromoheptyl-3-octyl tridec-2-enoate (400 mg, 0.80 mmol, 2.3 equiv), 3-amino-1-propanol (26 mg, 0.3478 mmol, 1.0 equiv), KCO (144 mg, 1.0434 mmol, 3.0 equiv), CsCO (57 mg, 0.1739 mmol, 0.5 equiv) and NaI (26 mg, 0.1739 mmol, 0.5 equiv) in ACN (6 mL) was stirred at 85° C. for 48 hours. 40 mL of water was added and the mixture was extracted three times with 20 mL of ethyl acetate. The organic phase was washed three times with 40 mL of sodium chloride solution, filtered and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to give the target CPL-101 (145.15 mg, 20% yield) as a colorless oil.
[0321] LCMS: LC / MS (ESI) m / z: 916.7 (M+H) + .
[0322] 1HNMR(400MHz, CDCl3)δ5.54(s,2H),4.01–3.97(m,4H),3.77–3.74(m,2H),2.96(s,2H),2.90(s,1H),2.53–2.49(m,2H),1.9 9(ddd,J=31.2,16.6,9.0Hz,10H),1.37(dd,J=3.4,1.3Hz,2H),1.29(s,6H),1.21(d,J=14.6Hz,70H),0.82(d,J=6.5Hz,12H).
[0323] Example 36: Preparation of ((3-hydroxypropyl)azadiyl)bis(octane-8,1-diyl)(2E,2'E)-bis(3-pentylnon-2-enoate) (CPL-112)
[0324] A mixture of (E)-8-bromooctanyl-3-pentylnon-2-enoate (400 mg, 0.9615 mmol, 2.3 equiv), 3-amino-1-propanol (31 mg, 0.4181 mmol, 1.0 equiv), KCO (173 mg, 1.2543 mmol, 3.0 equiv), CsCO (68 mg, 0.2091 mmol, 0.5 equiv) and NaI (31 mg, 0.2091 mmol, 0.5 equiv) in ACN (8 mL) was stirred at 85° C. for 48 hours. 40 mL of water was added and the mixture was extracted three times with 20 mL of ethyl acetate. The organic phase was washed three times with 40 mL of sodium chloride solution, filtered and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to give the target CPL-112 (118.53 mg, 17% yield) as a colorless oil.
[0325] LC / MS (ESI) m / z: 748.7 (M+H) + .
[0326] 1HNMR(400MHz, CDCl3)δ5.54(s,2H),4.00(t,J=6.7Hz,4H),3.77–3.66(m,2H),2.52(dd,J=20.6,13.0Hz,6H),2. 34(s,2H),2.10–2.02(m,4H),1.61–1.53(m,8H),1.38(d,J=5.1Hz,8H),1.30–1.17(m,40H),0.85–0.80(m,12H).
[0327] Example 37: Preparation of ((3-hydroxypropyl)azepinediyl)bis(nonane-9,1-diyl)(2E,2'E)-bis(3-propylundec-2-enoate) (CPL-127)
[0328] A mixture of (E)-9-bromononanyl-3-propanyl undec-2-enoate (514 mg, 1.193 mmol, 2.4 equiv), 3-amino-1-propanol (37 mg, 0.497 mmol, 1.0 equiv), KCO (275 mg, 1.988 mmol, 4.0 equiv) and NaI (37 mg, 0.249 mmol, 0.5 equiv) in ACN (4 mL) was stirred at 80° C. for 40 h. The mixture was concentrated and purified by preparative HPLC to give the target CPL-127 (200.08 mg, 51.89% yield) as a colorless oil.
[0329] LCMS:LC / MS(ESI)m / z:775.71(M+H) + .
[0330] 1H NMR (400MHz, CDCL3) δ5.62-5.61(m,2H),4.09-4.05(m,4H),3.80(t,J=5.2Hz,2H),2.70-2.66(m,2H),2.59-2 .54(m,4H),2.55-2.40(m,4H),2.14-2.09(m,4H),1.68-1.65(m,6H),1.35-1.26(m,53H),0.96-0.86(m,12H).
[0331] Example 38: Preparation of 9-((3-hydroxypropyl)(9-(E)-3-pentyltridec-2-enoyl)oxy)nonyl)amino)nonyl(Z)-3-pentyltridec-2-enoate (CPL-136)
[0332] A mixture of (E)-9-bromononanyl-3-pentyl tridec-2-enoate (600 mg, 1.23 mmol, 2.1 equiv), 3-amino-1-propanol (44 mg, 0.587 mmol, 1.0 equiv), KCO (324.02 mg, 2.348 mmol, 4.0 equiv) and NaI (43.92 mg, 0.293 mmol, 0.5 equiv) in ACN (5 mL) was stirred at 80° C. for 20 hours. 30 mL of water was added and the mixture was extracted three times with 20 mL of ethyl acetate. The organic phase was washed three times with 30 mL of sodium chloride solution, filtered and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to give the target CPL-136 (269.34 mg, 51.63% yield) as a colorless oil.
[0333] LCMS (ESI) m / z: 888.83 (M+H) + .
[0334] 1H NMR(400MHz,Chloroform-d)δ5.61(s,2H),4.07(t,J=6.8Hz,4H),3.79(t,J=5.1Hz,2H),2.70–2.61(m,2H),2.61–2.52(m,4H),2.46–2. 36(m,4H),2.12(t,J=7.7Hz,4H),2.09–1.99(m,2H),1.65–1.60(m,4H),1.47–1.43(m,6H),1.34–1.24(m,62H),0.89(d,J=6.2Hz,12H).
[0335] Example 39: Preparation of ((3-hydroxypropyl)azepinediyl)bis(decane-10,1-diyl)(2E,2'E)-bis(3-propyl phenoxy-2-enoate) (CPL-148)
[0336] A mixture of (E)-10-bromodecanyl-3-propanylnon-2-enoate (611 mg, 1.469 mmol, 2.4 eq), 3-amino-1-propanol (46 mg, 0.306 mmol, 0.5 eq), KCO (338 mg, 2.448 mmol, 4.0 eq) and NaI (46 mg, 0.306 mmol, 0.5 eq) in ACN (4 mL) was stirred at 80° C. for 40 h. The mixture was concentrated and purified by preparative HPLC to give the target CPL-148 (151.61 mg, 33.18% yield) as a colorless oil.
[0337] LCMS:LC / MS(ESI)m / z:747.67(M+H) + .
[0338] 1H NMR (400MHz, CDCL3) δ5.62-5.61(m,2H),4.09-4.05(m,4H),3.80(t,J=5.2Hz,2H),2.70-2.66(m,2H),2.59-2 .54(m,4H),2.55-2.40(m,4H),2.14-2.09(m,4H),1.68-1.65(m,6H),1.35-1.26(m,49H),0.96-0.86(m,12H).
[0339] Example 40: Preparation of ((3-hydroxypropyl)azadiylbis(decane-10,1-diyl)(2Z,2'Z)-bis(3-butylnon-2-enoate) (CPL-152)
[0340] A mixture of (E)-10-bromodecanyl-3-butylnon-2-enoate (215 mg, 0.5 mmol, 2.1 equiv), 3-amino-1-propanol (17.86 mg, 0.238 mmol, 1.0 equiv), KCO (131.38 mg, 0.952 mmol, 4.0 equiv) and NaI (17.84 mg, 0.119 mmol, 0.5 equiv) in ACN (5 mL) was stirred at 80° C. for 20 hours. 30 mL of water was added and the mixture was extracted three times with 20 mL of ethyl acetate. The organic phase was washed three times with 30 mL of sodium chloride solution, filtered and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to give the target CPL-152 (103.64 mg, 56.13% yield) as a colorless oil.
[0341] LCMS (ESI) m / z: 776.71 (M+H) + .
[0342] 1H NMR(400MHz,Chloroform-d)δ5.61(s,2H),4.07(t,J=6.8Hz,4H),3.83(t,J=5.3Hz,2H),2.95(d,J=63.2Hz, 4H),2.58(m,4H),2.17–2.09(m,4H),1.91(s,2H),1.62(d,J=7.2Hz,6H),1.45–1.25(m,52H),0.89(m,12H).
[0343] Example 41: Preparation of ((3-hydroxypropyl)azadiyl)bis(undecane-11,1-diyl)(2E,2'E)-bis(3-butyldec-2-enoate) (CPL-184)
[0344] A mixture of (E)-11-bromondecyl-3-butyldec-2-enoate (154 mg, 0.95 mmol, 2.1 equiv), 3-amino-1-propanol (11.25 mg, 0.15 mmol, 1.0 equiv), KCO (82.8 mg, 0.6 mmol, 4.0 equiv) and NaI (11 mg, 0.075 mmol, 0.5 equiv) in ACN (5 mL) was stirred at 80° C. for 20 hours. 30 mL of water was added and the mixture was extracted three times with 20 mL of ethyl acetate. The organic phase was washed three times with 30 mL of sodium chloride solution, filtered and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to give the target CPL-184 (26.73 mg, 9% yield) as a colorless oil.
[0345] LCMS (ESI) m / z: 832.39 (M+H)+ .
[0346] 1H NMR(400MHz, CDCl3)δ5.61(s,2H),4.07(t,J=6.7Hz,4H),3.86–3.74(m,2H),2.69–2.52( m,6H),2.45–2.36(m,4H),2.12(d,J=6.8Hz,4H),1.52–1.24(m,69H),0.94–0.87(m,12H).
[0347] Example 42: Preparation of 3-(((E)-3-butyloct-2-enoyl)oxy)-2-((((2-(dimethylamino)ethoxy)carbonyl)oxy)methyl)propyl (9Z,12Z)-octadec-9,12-dienoate (CPL-199)
[0348] A mixture of 3-((E)-3-butaneoct-2-enoate)-2-(hydroxymethyl)propane-(9Z,12Z)-octa-9,12-dienoate (250 mg, 0.27 mmol, 1.0 equiv), pyridine (216 mg, 2.73 mmol, 10.0 equiv) and triphosgene (33 mg, 0.10 mmol, 0.4 equiv) in dichloromethane (3 mL) was stirred at 0°C for 30 minutes. N,N-dimethylethanolamine (74 mg, 0.82 mmol, 3.0 equiv) was added and stirred at 30°C for 16 hours. 10 mL of water was added and extracted three times with 10 mL of dichloromethane. The organic phase was washed three times with 20 mL of sodium chloride solution, filtered and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to give the target CPL-199 (62 mg, 34% yield) as a colorless oil.
[0349] LC / MS (ESI) m / z: 664.6 (M+H) + .
[0350] 1H NMR (400MHz, CDCl3) δ5.61(s,1H),5.46–5.19(m,4H),4.33–3.98(m,8H),2.83–2.69(m,2H),2.68–2.53(m,4H),2.50–2. 38(m,1H),2.36–2.29(m,4H),2.28(s,6H),2.17–2.10(m,2H),2.09–1.99(m,4H),1.50–1.23(m,26H),0.99–0.84(m,9H).
[0351] Example 43: Preparation of 3-((((2-(dimethylamino)ethoxy)carbonyl)oxy)-2-((((E)-3-hexylundecan-2-enoyl)oxy)methyl)propyl (9Z,12Z)-octadec-9,12-dienoate (CPL-203)
[0352] A mixture of 3-((E)-3-hexyl undec-2-enoate)-2-(hydroxymethyl)propanyl-(9Z,12Z)-octa-9,12-dienoate (200 mg, 0.339 mmol, 1.0 equiv), pyridine (268 mg, 3.39 mmol, 10.0 equiv), and triphosgene (41 mg, 0.136 mmol, 0.4 equiv) in dichloromethane (3 mL) was stirred at 0° C. for 30 minutes. N,N-dimethylethanolamine (61 mg, 0.678 mmol, 2.0 equiv) was added and stirred at 30° C. for 16 hours. 10 mL of water was added and the mixture was extracted three times with 10 mL of dichloromethane. The organic phase was washed three times with 20 mL of sodium chloride solution, filtered, and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to give the target CPL-203 (40 mg, 16.8% yield) as a colorless oil.
[0353] LC / MS (ESI) m / z: 706.6 (M+H) + .
[0354] 1H NMR(400MHz, CDCl3)δ5.60(s,1H),5.46–5.30(m,4H),4.34–4.07(m,8H),2.85–2.71(m,2H),2.71–2.62(m,2H),2. 62–2.54(m,2H),2.48–2.23(m,9H),2.18–2.09(m,2H),2.09–1.94(m,5H),1.69–1.20(m,30H),0.91–0.82(m,9H).
[0355] Example 44: Preparation of 3-(((2-(dimethylamino)ethoxy)carbonyl)oxy)-2-((((E)-3-heptylundeca-2-enoyl)oxy)methyl)propyl (9Z,12Z)-octadec-9,12-dienoate (CPL-208)
[0356] A mixture of 3-((E)-3-heptyl undec-2-enoate)-2-(hydroxymethyl)propanyl-(9Z,12Z)-octa-9,12-dienoate (200 mg, 0.316 mmol, 1.0 equiv), pyridine (249.9 mg, 3.16 mmol, 10.0 equiv) and triphosgene (38.57 mg, 0.13 mmol, 0.4 equiv) in dichloromethane (5 mL) was stirred at 0°C for 30 minutes. N,N-dimethylpropanolamine (56.29 mg, 0.632 mmol, 2.0 equiv) was added and stirred at room temperature for 16 hours. 30 mL of water was added and the mixture was extracted three times with 20 mL of dichloromethane. The organic phase was washed three times with 30 mL of sodium chloride solution, filtered and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to give target CPL-208 (28.01 mg, 11.84% yield) as a colorless oil.
[0357] LCMS (ESI) m / z: 748.6 (M+H) + .
[0358] 1H NMR(400MHz,Chloroform-d)δ5.60(s,1H),5.40–5.29(m,4H),4.32–4.19(m,4H),4.15(m,4H),2.81–2.61(m,4H),2.61–2.54(m,2H),2.4 4(m,1H),2.42–2.25(m,8H),2.13(t,J=7.7Hz,2H),2.04(t,J=6.9Hz,4H),1.44(d,J=7.3Hz,2H),1.38–1.25(m,36H),0.91–0.86(m,9H).
[0359] Example 45: Preparation of 3-(((2-(dimethylamino)ethoxy)carbonyl)oxy)-2-(((3-octylundecan-2-enoyl)oxy)methyl)propyl (9Z,12Z)-octadec-9,12-dienoate (CPL-210)
[0360] A mixture of 3-((E)-3-octyl undec-2-enoate)-2-(hydroxymethyl)propanyl-(9Z,12Z)-octa-9,12-dienoate (200 mg, 0.3096 mmol, 1.0 equiv), N,N-dimethylpropanolamine (55 mg, 0.6192 mmol, 2.0 equiv), pyridine (245 mg, 3.096 mmol, 10.0 equiv), and triphosgene (37 mg, 0.1238 mmol, 0.4 equiv) in dichloromethane (7 mL) was stirred at room temperature for 16 hours. 40 mL of water was added, and the mixture was extracted three times with 20 mL of dichloromethane. The organic phase was washed three times with 40 mL of sodium chloride solution, filtered, and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to afford the target CPL-210 (25.97 mg, 11% yield) as a colorless oil.
[0361] LC / MS (ESI) m / z: 761.62 (M+H) + .
[0362] 1H NMR(400MHz, CDCl3)δ5.60(s,1H),5.43–5.29(m,4H),4.25–4.18(m,4H),4.17–4.10(m,4H),2.77(t,J=6.4Hz,2H),2.58(dd,J=15.0,7.3Hz,3H),2.4 8–2.31(m,2H),2.29(s,6H),2.12(dd,J=18.8,10.9Hz,2H),2.07–2.01(m, 4H), 1.44 (dd, J=14.6, 7.0Hz, 4H), 1.36–1.23 (m, 38H), 0.90–0.86 (m, 9H).
[0363] Example 46: Preparation of 3-(((Z)-3-butylnon-2-enoyl)oxy)-2-((((3-(dimethylamino)propyloxy)carbonyl)oxy)methyl)propyl (9Z,12Z)-octadec-9,12-dienoate (CPL-218)
[0364] A mixture of 3-((E)-3-butanenon-2-enoate)-2-(hydroxymethyl)propane-(9Z,12Z)-octa-9,12-dienoate (150 mg, 0.267 mmol, 1.0 equiv), pyridine (212.2 mg, 2.67 mmol, 10.0 equiv) and triphosgene (31.69 mg, 0.107 mmol, 0.4 equiv) in dichloromethane (2 mL) was stirred at 0 ° C for 30 minutes. N, N-dimethylpropanolamine (54.95 mg, 0.533 mmol, 2.0 equiv) was added and stirred at room temperature for 16 hours. 30 mL of water was added and extracted three times with 20 mL of dichloromethane. The organic phase was washed three times with 30 mL of sodium chloride solution, filtered and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to give the target CPL-218 (27.16 mg, 14.71% yield) as a colorless oil.
[0365] LCMS (ESI) m / z: 692.54 (M+H) + .
[0366] 1H NMR(400MHz,Chloroform-d)δ5.61(s,1H),5.42–5.29(m,4H),4.25–4.12(m,8H),2.77(t,J=6.5Hz,2H),2.63–2.53(m,2H),2.45(m,1H), 2.39(t,J=7.3Hz,2H),2.31(t,J=7.6Hz,2H),2.25(s,6H),2.18–2.11(m,2H),2.05(m,4H),1.43(m,4H),1.40–1.21(m,26H),0.90(m,9H).
[0367] Example 47: Preparation of 3-(((E)-3-butyloct-2-enoyl)oxy)-2-((((3-(dimethylamino)propyloxy)carbonyl)oxy)methyl)propyl (9Z,12Z)-octadec-9,12-dienoate (CPL-221)
[0368] A mixture of 3-((E)-3-butyloct-2-enoate)-2-(hydroxymethyl)propanyl-(9Z,12Z)-octa-9,12-dienoate (150 mg, 0.27 mmol, 1.0 equiv), pyridine (216 mg, 2.73 mmol, 10.0 equiv), and triphosgene (33 mg, 0.10 mmol, 0.4 equiv) in dichloromethane (3 mL) was stirred at 0°C for 30 minutes. N,N-dimethylpropanolamine (83 mg, 0.82 mmol, 3.0 equiv) was added and stirred at room temperature for 16 hours. 10 mL of water was added and the mixture was extracted three times with 10 mL of dichloromethane. The organic phase was washed three times with 20 mL of sodium chloride solution, filtered, and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to give the target CPL-221 (60 mg, 32% yield) as a colorless oil.
[0369] LC / MS (ESI) m / z: 678.6 (M+H) + .
[0370] 1H NMR(400MHz, CDCl3)δ5.61(s,1H),5.48–5.20(m,4H),4.31–4.01(m,8H),2.82–2.69(m,2H),2.64–2.50(m,2H),2.50–2.39(m,1H) ,2.38–2.28(m,4H),2.23(s,6H),2.17–2.10(m,2H),2.09–2.00(m,4H),1.90–1.78(m,2H),1.50–1.24(m,26H),0.97–0.85(m,9H).
[0371] Example 48: Preparation of 3-(((3-(dimethylamino)propyloxy)carbonyl)oxy)-2-((((E)-3-pentylnon-2-enoyl)oxy)methyl)propyl (9Z,12Z)-octadec-9,12-dienoate (CPL-222)
[0372] A mixture of 3-((E)-3-pentylnon-2-enoate)-2-(hydroxymethyl)propanyl-(9Z,12Z)-octadec-9,12-dienoate (200 mg, 0.3472 mmol, 1.0 equiv), N,N-dimethylpropanolamine (72 mg, 0.6944 mmol, 2.0 equiv), pyridine (274 mg, 3.472 mmol, 10.0 equiv), and triphosgene (41 mg, 0.1389 mmol, 0.4 equiv) in dichloromethane (8 mL) was stirred at room temperature for 16 hours. 40 mL of water was added, and the mixture was extracted three times with 20 mL of dichloromethane. The organic phase was washed three times with 40 mL of sodium chloride solution, filtered, and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to give the target CPL-222 (71.12 mg, 29% yield) as a colorless oil.
[0373] LC / MS (ESI) m / z: 705.9 (M+H) + .
[0374] 1HNMR(400MHz, CDCl3)δ5.54(s,1H),5.33–5.21(m,4H),4.16–4.07(m,8H),2.70 (t,J=6.5Hz,2H),2.55–2.47(m,2H),2.39–2.29(m,3H),2.24(t,J=7.6Hz,2H),2. 18(s,6H),2.09–2.04(m,2H),1.98(q,J=6.9Hz,4H),1.82–1.75(m,2H),1.38(dd, J=10.0,6.4Hz,4H),1.22(dd,J=13.9,11.3Hz,26H),0.82(dd,J=7.0,4.4Hz,9H).
[0375] Example 49: Preparation of 3-(((3-(dimethylamino)propyloxy)carbonyl)oxy)-2-((((E)-3-pentylundeca-2-enoyl)oxy)methyl)propyl (9Z,12Z)-octadec-9,12-dienoate (CPL-223)
[0376] A mixture of 3-((E)-3-pentyl undec-2-enoate)-2-(hydroxymethyl)propanyl-(9Z,12Z)-octa-9,12-dienoate (150 mg, 0.237 mmol, 1.0 equiv), pyridine (188 mg, 2.37 mmol, 10.0 equiv), and triphosgene (29 mg, 0.09 mmol, 0.4 equiv) in dichloromethane (3 mL) was stirred at 0°C for 30 minutes. A solution of N,N-dimethylpropanolamine (73 mg, 0.71 mmol, 3.0 equiv) in 1 mL of dichloromethane was added, and the mixture was stirred at 30°C for 16 hours. 10 mL of water was added, and the mixture was extracted three times with 10 mL of dichloromethane. The organic phase was washed three times with 20 mL of sodium chloride solution, filtered, and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to give the target CPL-223 (36 mg, 21% yield) as a colorless oil.
[0377] LC / MS (ESI) m / z: 734.6 (M+H) + .
[0378] 1H NMR(400MHz, CDCl3)δ5.61(s,1H),5.44–5.26(m,4H),4.30–4.00(m,8H),2.84–2.69(m,2H),2.62–2.53(m,2H),2.49–2.39(m,1H) ,2.39–2.27(m,4H),2.23(s,6H),2.17–2.10(m,2H),2.10–1.99(m,4H),1.92–1.78(m,2H),1.47–1.27(m,34H),0.96–0.85(m,9H).
[0379] Example 50: Preparation of 3-(((3-(dimethylamino)propyloxy)carbonyl)oxy)-2-((((E)-3-pentyltridec-2-enoyl)oxy)methyl)propyl (9Z,12Z)-octadec-9,12-dienoate (CPL-224)
[0380] A mixture of 3-((E)-3-pentyl tridec-2-enoate)-2-(hydroxymethyl)propanyl-(9Z,12Z)-octa-9,12-dienoate (200 mg, 0.327 mmol, 1.0 equiv), pyridine (252 mg, 3.2 mmol, 10.0 equiv) and triphosgene (37 mg, 0.128 mmol, 0.4 equiv) in dichloromethane (2 mL) was stirred at 0°C for 30 minutes. N,N-dimethylpropanolamine (98.9 mg, 0.96 mmol, 3.0 equiv) was added and stirred at room temperature for 16 hours. 30 mL of water was added and extracted three times with 20 mL of dichloromethane. The organic phase was washed three times with 30 mL of sodium chloride solution, filtered and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to give the target CPL-224 (45.26 mg, 18% yield) as a colorless oil.
[0381] Example 51: Preparation of 3-(((3-(dimethylamino)propyloxy)carbonyl)oxy)-2-((((E)-3-heptyltridec-2-enoyl)oxy)methyl)propyl (9Z,12Z)-octadec-9,12-dienoate (CPL-231)
[0382] A mixture of 3-((E)-3-heptyl tridec-2-enoate)-2-(hydroxymethyl)propane-(9Z,12Z)-octa-9,12-dienoate (200 mg, 0.303 mmol, 1.0 equiv), pyridine (239.67 mg, 3.03 mmol, 10.0 equiv) and triphosgene (35.90 mg, 0.121 mmol, 0.4 equiv) in dichloromethane (5 mL) was stirred at 0 ° C for 30 minutes. N, N-dimethylpropanolamine (62.48 mg, 0.606 mmol, 2.0 equiv) was added and stirred at room temperature for 16 hours. 30 mL of water was added and extracted three times with 20 mL of dichloromethane. The organic phase was washed three times with 30 mL of sodium chloride solution, filtered and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to give the target CPL-231 (51.52 mg, 21.5% yield) as a colorless oil.
[0383] LCMS (ESI) m / z: 790.65 (M+H) + .
[0384] 1H NMR(400MHz,Chloroform-d)δ5.60(s,1H),5.35(m,4H),4.23–4.13(m,8H),2.77(t,J=6.5Hz,2H),2.61–2.53(m,2H),2.49–2.42(m,1H),2.39( t,J=7.5Hz,2H),2.31(t,J=7.6Hz,2H),2.25(s,6H),2.13(t,J=7.7Hz, 2H),2.05(m,4H),1.86(m,2H),1.44(m,6H),1.28(m,36H),0.88(m,9H).
[0385] Example 52: Preparation of 3-((3-decyltridecyl-2-enoyl)oxy)-2-((((3-(dimethylamino)propyloxy)carbonyl)oxy)methyl)propyl(9Z,12Z)-octadec-9,12-dienoate (CPL-234)
[0386] A mixture of 3-((E)-3-decyltridec-2-enoate)-2-(hydroxymethyl)propanyl-(9Z,12Z)-octadec-9,12-dienoate (190 mg, 0.2707 mmol, 1.0 equiv), N,N-dimethylpropanolamine (56 mg, 0.5413 mmol, 2.0 equiv), pyridine (214 mg, 2.707 mmol, 10.0 equiv), and triphosgene (32 mg, 0.1083 mmol, 0.4 equiv) in dichloromethane (8 mL) was stirred at room temperature for 16 hours. 40 mL of water was added, and the mixture was extracted three times with 20 mL of dichloromethane. The organic phase was washed three times with 40 mL of sodium chloride solution, filtered, and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to give the target CPL-234 (40.04 mg, 18% yield) as a colorless oil.
[0387] LC / MS (ESI) m / z: 832.7 (M+H) + .
[0388] 1HNMR (400MHz, CDCl3) δ5.53(s,1H),5.31–5.22(m,4H),4.17–4.05(m,8H),2.70(t,J=6.2Hz,2H),2.55–2.47(m,2H),2.33(dd,J=14.9,7.4Hz,2H ),2.27–2.15(m,9H),2.09–2.02(m,2H),1.98(q,J=6.7Hz,5H),1.84–1. 73(m,3H),1.37(d,J=4.5Hz,4H),1.24–1.17(m,42H),0.83–0.80(m,9H).
[0389] Example 53: Preparation of 3-(((4-(dimethylamino)butoxy)carbonyl)oxy)-2-(((E)-3-heptylundeca-2-enoyl)oxy)methyl)propyl (9Z,12Z)-octadec-9,12-dienoate (CPL-252)
[0390] A mixture of 3-((E)-3-heptyl undec-2-enoate)-2-(hydroxymethyl)propanyl-(9Z,12Z)-octa-9,12-dienoate (200 mg, 0.316 mmol, 1.0 equiv), pyridine (249.9 mg, 3.16 mmol, 10.0 equiv), and triphosgene (38.57 mg, 0.130 mmol, 0.4 equiv) in dichloromethane (5 mL) was stirred at 0°C for 30 minutes. N,N-dimethylbutanolamine (74.02 mg, 0.632 mmol, 2.0 equiv) was added, and the mixture was stirred at room temperature for 16 hours. 30 mL of water was added, and the mixture was extracted three times with 20 mL of dichloromethane. The organic phase was washed three times with 30 mL of sodium chloride solution, filtered, and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to give the target CPL-252 (30.28 mg, 12.3% yield) as a colorless oil.
[0391] LCMS (ESI) m / z: 776.63 (M+H) + .
[0392] 1H NMR(400MHz,Chloroform-d)δ5.61(d,J=6.2Hz,1H),5.42–5.29(m,4H),4.26–4.09(m,8H),2.77(t,J=6.5Hz,2H),2.58(t,J=7.8Hz,2H),2.44( m,1H),2.35–2.18(m,10H),2.13(t,J=7.7Hz,2H),2.06(t,J=6.6Hz,4H),1.70(m,2H),1.44(d,J=7.6Hz,4H),1.37–1.24(m,36H),0.89(m,9H).
[0393] Example 54: Preparation of 3-((3-decyltridecyl-2-enoyl)oxy)-2-((((4-(dimethylamino)butoxy)carbonyl)oxy)methyl)propyl (9Z,12Z)-octadec-9,12-dienoate (CPL-256)
[0394] A mixture of 3-((E)-3-decyltridec-2-enoate)-2-(hydroxymethyl)propanyl-(9Z,12Z)-octa-9,12-dienoate (190 mg, 0.2707 mmol, 1.0 equiv), N,N-dimethylbutanolamine (63 mg, 0.5413 mmol, 2.0 equiv), pyridine (214 mg, 2.707 mmol, 10.0 equiv), and triphosgene (32 mg, 0.1083 mmol, 0.4 equiv) in dichloromethane (6 mL) was stirred at room temperature for 16 hours. 40 mL of water was added, and the mixture was extracted three times with 20 mL of dichloromethane. The organic phase was washed three times with 40 mL of sodium chloride solution, filtered, and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to give the target CPL-256 (36.08 mg, 16% yield) as a colorless oil.
[0395] LC / MS (ESI) m / z: 846.7 (M+H) + .
[0396] 1HNMR(400MHz, CDCl3)δ5.53(s,1H),5.35–5.21(m,4H),4.18–4.03(m,8H),2. 70(t,J=6.5Hz,2H),2.55–2.45(m,2H),2.37(dt,J=9.2,4.7Hz,1H),2.27–2.1 8(m,4H),2.14(s,6H),2.09–2.03(m,2H),1.98(q,J=6.6Hz,5H),1.63(dd,J=1 3.0, 6.3Hz, 3H), 1.35 (d, J = 4.7Hz, 2H), 1.24–1.18 (m, 46H), 0.82–0.79 (m, 9H).
[0397] Example 55: Preparation of 3-(((3-(diethylamino)propyloxy)carbonyl)oxy)-2-((((E)-3-pentylnon-2-enoyl)oxy)methyl)propyl (9Z,12Z)-octadec-9,12-dienoate (CPL-266)
[0398] A mixture of 3-((E)-3-pentylnon-2-enoate)-2-(hydroxymethyl)propanyl-(9Z,12Z)-octadec-9,12-dienoate (200 mg, 0.3472 mmol, 1.0 equiv), N,N-diethylpropanolamine (91 mg, 0.6944 mmol, 2.0 equiv), pyridine (274 mg, 3.407 mmol, 10.0 equiv), and triphosgene (41 mg, 0.1389 mmol, 0.4 equiv) in dichloromethane (8 mL) was stirred at room temperature for 16 hours. 40 mL of water was added, and the mixture was extracted three times with 20 mL of dichloromethane. The organic phase was washed three times with 40 mL of sodium chloride solution, filtered, and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to give the target CPL-266 (35.80 mg, 14% yield) as a colorless oil.
[0399] LC / MS (ESI) m / z: 735.1 (M+H) + .
[0400] 1HNMR(400MHz, CDCl3)δ5.54(s,1H),5.33–5.22(m,4H),4.16–4.07(m,8H),2 .70(t,J=6.5Hz,2H),2.53–2.34(m,9H),2.24(t,J=7.6Hz,2H),2.10–2.03(m ,2H),1.98(q,J=6.8Hz,4H),1.77(s,2H),1.38(dd,J=8.5,5.5Hz,4H),1.22( dd,J=13.9,11.3Hz,26H),0.97(t,J=7.0Hz,6H),0.82(dd,J=7.0,4.3Hz,9H).
[0401] Example 56: Preparation of 3-(((3-(diethylamino)propyloxy)carbonyl)oxy)-2-((((E)-3-heptylundeca-2-enoyl)oxy)methyl)propyl (9Z,12Z)-octadec-9,12-dienoate (CPL-274)
[0402] A mixture of 3-((E)-3-heptyl undec-2-enoate)-2-(hydroxymethyl)propanyl-(9Z,12Z)-octa-9,12-dienoate (200 mg, 0.316 mmol, 1.0 equiv), pyridine (249.9 mg, 3.16 mmol, 10.0 equiv) and triphosgene (38.57 mg, 0.130 mmol, 0.4 equiv) in dichloromethane (5 mL) was stirred at 0°C for 30 minutes. N,N-diethylpropanolamine (82.93 mg, 0.632 mmol, 2.0 equiv) was added and stirred at room temperature for 16 hours. 30 mL of water was added and the mixture was extracted three times with 20 mL of dichloromethane. The organic phase was washed three times with 30 mL of sodium chloride solution, filtered and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to give the target CPL-274 (34.53 mg, 13.8% yield) as a colorless oil.
[0403] LCMS (ESI) m / z: 790.65 (M+H) + .
[0404] 1H NMR(400MHz,Chloroform-d)δ5.60(s,1H),5.41–5.30(m,4H),4.23–4.14(m,8H),2.77(t,J=6.5Hz,2H),2.67–2.38(m,9H),2.30(t,J =7.6Hz,2H),2.13(t,J=7.7Hz,2H),2.04(t,J=6.9Hz,4H),1.84(s,2H),1.48–1.40(m,4H),1.35–1.25(m,34H),1.04(s,6H),0.89(m, 9H).
[0405] Example 57: Preparation of 3-(((2-(1-methylpiperidin-4-yl)ethoxy)carbonyl)oxy)-2-((((E)-3-propylnon-2-enoyl)oxy)methyl)propyl (9Z,12Z)-octadec-9,12-dienoate (CPL-280)
[0406] 3-((E)-3-Propanylnon-2-enoate)-2-(hydroxymethyl)propanyl-(9Z,12Z)-octadec-9,12-dienoate (183 mg, 0.334 mmol, 1.0 equiv) and triphosgene (39 mg, 0.133 mmol, 0.4 equiv) were mixed in dichloromethane (6 mL). 4-Dimethylaminopyridine (81 mg, 0.668 mmol, 2.0 equiv) was added dropwise at 0°C under nitrogen protection and stirred for 20 minutes. N-Methyl-4-(2-hydroxyethyl)piperidine (95 mg, 0.668 mmol, 2.0 equiv) was added dropwise and stirred at room temperature overnight. 15 mL of ice water was added and the mixture was extracted three times with 20 mL of dichloromethane. The organic phase was washed three times with 20 mL of sodium chloride solution, filtered, and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to give the target CPL-280 (72 mg, 30.1% yield) as a colorless oil.
[0407] LC / MS (ESI) m / z: 718.7 (M+H) + .
[0408] 1H NMR(400MHz,CDCL3)δ5.62(d,J=5.2Hz,1H),5.40-5.31(m,4H),4.22-4.12(m,8H),2.78-2.72(m,4H),2.65-2.54(m,3H),2.45-2.42(m,1H) ,2.32(t,J=7.6Hz,2H),2.15-2.10(m,2H),2.07-1.99(m,5H),1.95-1 .80(m,3H),1.72-1.57(m,4H),1.52-1.25(m,29H),0.97-0.83(m,9H).
[0409] Example 58: Preparation of 3-(((2-(1-methylpiperidin-4-yl)ethoxy)carbonyl)oxy)-2-((((E)-3-pentylundecan-2-enoyl)oxy)methyl)propyl (9Z,12Z)-octadecane-9,12-dienoate (CPL-289)
[0410] A mixture of 3-((E)-3-pentyl undec-2-enoate)-2-(hydroxymethyl)propanyl-(9Z,12Z)-octa-9,12-dienoate (100 mg, 0.1653 mmol, 1.0 equiv), N-methyl-4-(2-hydroxyethyl)piperidine (71.03 mg, 0.4959 mmol, 3.0 equiv), pyridine (130.76 mg, 1.65 mmol, 10.0 equiv), and triphosgene (19.62 mg, 0.0601 mmol, 0.4 equiv) in dichloromethane (5 mL) was stirred at room temperature for 16 hours. 40 mL of water was added, and the mixture was extracted three times with 20 mL of dichloromethane. The organic phase was washed three times with 40 mL of sodium chloride solution, filtered, and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to give the target CPL-289 (89.14 mg, 64.66% yield) as a colorless oil.
[0411] LC / MS (ESI) m / z: 774.8 (M+H) + .
[0412] 1HNMR (400MHz, CDCl3) δ5.60 (s, 1H), 5.37–5.31 (m, 4H), 4.20 (d, J = 4.8Hz, 2H), 4.18 –4.14(m,6H),2.82(s,2H),2.76(d,J=6.4Hz,2H),2.61–2.55(m,2H),2.46–2.42(m,1H),2.30(d,J=6.8Hz,2H),2.26(s,2H ), 2.12 (d, J = 7.4Hz, 2H), 2.03 (d, J = 5.8Hz, 3H), 1.91 (d, J = 12.4Hz, 2H), 1.61 (s, 6H), 1.25 (s, 36H), 0.89 (d, J = 2.8Hz, 10H).
[0413] Example 59: Preparation of 3-(((2-(1-methylpiperidin-4-yl)ethoxy)carbonyl)oxy)-2-(((E)-3-pentyltridec-2-enoyl)oxy)methyl)propyl (9Z,12Z)-octadec-9,12-dienoate (CPL-290)
[0414] A mixture of 3-((E)-3-pentyl tridec-2-enoate)-2-(hydroxymethyl)propanyl-(9Z,12Z)-octa-9,12-dienoate (300 mg, 0.45 mmol, 1.0 equiv), pyridine (308.50 mg, 4.5 mmol, 10.0 equiv) and triphosgene (46.29 mg, 0.18 mmol, 0.4 equiv) in dichloromethane (5 mL) was stirred at 0°C for 30 minutes. N-methyl-4-(2-hydroxyethyl)piperidine (113.13 mg, 0.90 mmol, 2.0 equiv) was added and stirred at room temperature for 16 hours. 30 mL of water was added and the mixture was extracted three times with 20 mL of dichloromethane. The organic phase was washed three times with 30 mL of sodium chloride solution, filtered and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to give the target CPL-290 (32.51 mg, 8.99% yield) as a colorless oil.
[0415] LCMS (ESI) m / z: 803.1 (M+H) + .
[0416] 1H NMR(400MHz,Chloroform-d)δ5.60(s,1H),5.43–5.28(m,4H),4.23–4.14(m,8H), 2.87(d,J=11.3Hz,2H),2.77(t,J=6.5Hz,2H),2.62–2.54(m,2H),2.49–2.40(m,1 H),2.31(d,J=7.5Hz,2H),2.28(d,J=1.6Hz,3H),2.16–2.10(m,2H),2.05(q,J=6. 9Hz,4H),1.95(t,J=11.4Hz,2H),1.76–1.67(m,3H),0.89(tt,J=4.2,2.4Hz,9H).
[0417] Example 60: Preparation of 3-(((E)-3-hexylundec-2-enoyl)oxy)-2-((((2-(1-methylpiperidin-4-yl)ethoxy)carbonyl)oxy)methyl)propyl (9Z,12Z)-octadec-9,12-dienoate (CPL-292)
[0418] A mixture of 3-((E)-3-hexyl undec-2-enoate)-2-(hydroxymethyl)propanyl-(9Z,12Z)-octa-9,12-dienoate (150 mg, 0.24 mmol, 1.0 equiv), pyridine (0.2 mL, 2.5 mmol, 10.0 equiv), and triphosgene (30 mg, 0.101 mmol, 0.4 equiv) in dichloromethane (3 mL) was stirred at 0°C for 30 minutes. N-methyl-4-(2-hydroxyethyl)piperidine (75 mg, 0.52 mmol, 2.0 equiv) was added and stirred at room temperature for 16 hours. 30 mL of water was added and the mixture was extracted three times with 20 mL of dichloromethane. The organic phase was washed three times with 30 mL of sodium chloride solution, filtered, and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to give the target CPL-292 (17.10 mg, 8.95% yield) as a colorless oil.
[0419] LCMS (ESI) m / z: 788.6 (M+H) + .
[0420] 1H NMR(400MHz,Chloroform-d)δ5.60(s,1H),5.35(s,4H),4.24–4.10(m,6H),3.99(d,J=4.6Hz,2H),2.98(s,2H),2.77(s,2H),2.57(s,2H),2. 42(d,J=11.8Hz,2H),2.36–2.24(m,3H),2.12(d,J=8.0Hz,2H),2.04(d,J=6.8Hz,8H),1.74(s,4H),1.47–1.05(m,63H),0.94–0.74(m,18H).
[0421] Example 61: Preparation of 3-(((3-(dimethylamino)-2,2-dimethylpropyloxy)carbonyl)oxy)-2-((((E)-3-propyl-2-enoyl)oxy)methyl)propyl (9E,12E)-octadec-9,12-dienoate (CPL-304)
[0422] 3-((E)-3-Propanyl tridec-2-enoate)-2-(hydroxymethyl)propanyl-(9Z,12Z)-octadec-9,12-dienoate (237 mg, 0.392 mmol, 1.0 equiv) and triphosgene (46 mg, 0.157 mmol, 0.4 equiv) were mixed in dichloromethane (4 mL). 4-Dimethylaminopyridine (95 mg, 0.784 mmol, 2.0 equiv) was added dropwise at 0°C under nitrogen protection and stirred for 20 minutes. 3-Dimethylamino-2,2-dimethyl-1-propanol (103 mg, 0.784 mmol, 2.0 equiv) was added dropwise and stirred at room temperature overnight. 15 mL of ice water was added and the mixture was extracted three times with 20 mL of dichloromethane. The organic phase was washed three times with 20 mL of sodium chloride solution, filtered, and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to give the target CPL-304 (34 mg, 11.4% yield) as a colorless oil.
[0423] LC / MS (ESI) m / z: 762.6 (M+H) + .
[0424] 1H NMR (400MHz, CDCL3) δ5.55-5.53(m,1H),5.34-5.23(m,4H),4.15-4.08(m,6H),3.87(s,2H),2.71(t,J=6.4Hz,2H),2.51-2.47(m,2H),2.41-2 .35(m,1H),2.25-2.20(m,8H),2.09-2.03(m,4H),2.00-1.95(m,4H),1 .53(s,6H),1.47-1.35(m,4H),1.32-1.19(m,24H),0.89-0.76(m,15H).
[0425] Example 62: Preparation of 3-(((E)-3-butyloctyl-2-enoyl)oxy)-2-((((3-(dimethylamino)-2,2-dimethylpropyloxy)carbonyl)oxy)methyl)propyl (9Z,12Z)-octadec-9,12-dienoate (CPL-309)
[0426] A mixture of 3-((E)-3-butyloct-2-enoate)-2-(hydroxymethyl)propanyl-(9Z,12Z)-octadec-9,12-dienoate (150 mg, 0.27 mmol, 1.0 equiv), pyridine (216 mg, 2.73 mmol, 10.0 equiv), and triphosgene (33 mg, 0.10 mmol, 0.4 equiv) in dichloromethane (3 mL) was stirred at 0°C for 30 minutes. 3-Dimethylamino-2,2-dimethyl-1-propanol (130 mg, 0.82 mmol, 3.0 equiv) was added, and the mixture was stirred at room temperature for 16 hours. 10 mL of water was added, and the mixture was extracted three times with 10 mL of dichloromethane. The organic phase was washed three times with 20 mL of sodium chloride solution, filtered, and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to give target CPL-309 (95 mg, 49% yield) as a colorless oil.
[0427] LC / MS (ESI) m / z: 706.6 (M+H) + .
[0428] 1H NMR(400MHz, CDCl3)δ5.61(s,1H),5.46–5.26(m,4H),4.28–4.09(m,6H),3.95(s,2H),2.82–2.70(m,2H),2.63–2.54(m,2H),2.52–2.37( m,1H),2.32–2.28(m,4H),2.28(s,3H),2.19–2.10(m,4H),2.10–1.97(m,4H),1.66–1.60(m,2H),1.47–1.20(m,25H),1.00–0.75(m,15H).
[0429] Example 63: Preparation of 3-(((E)-3-butyldec-2-enoyl)oxy)-2-((((3-(dimethylamino)-2,2-dimethylpropyloxy)carbonyl)oxy)methyl)propyl (9Z,12Z)-octadec-9,12-dienoate (CPL-316)
[0430] A mixture of 3-((E)-3-butyldec-2-enoate)-2-(hydroxymethyl)propanyl-(9Z,12Z)-octa-9,12-dienoate (200 mg, 0.33 mmol, 1.0 equiv), pyridine (260.7 mg, 3.3 mmol, 10.0 equiv) and triphosgene (40 mg, 0.13 mmol, 0.4 equiv) in dichloromethane (2 mL) was stirred at 0°C for 30 minutes. 3-Dimethylamino-2,2-dimethyl-1-propanol (131 mg, 1.04 mmol, 3.0 equiv) was added and stirred at room temperature for 16 hours. 30 mL of water was added and the mixture was extracted three times with 20 mL of dichloromethane. The organic phase was washed three times with 30 mL of sodium chloride solution, filtered and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to give the target CPL-316 (98.2 mg, 76% yield) as a colorless oil.
[0431] LCMS (ESI) m / z: 734.12 (M+H) + .
[0432] 1H NMR(400MHz, CDCl3)δ5.61(s,1H),5.43–5.24(m,4H),4.22-4.12(m,6H),3.94(s,2H),2.77(s,2H),2.62–2.51(m,1H),2. 47–2.41(m,1H),2.36–2.23(m,8H),2.16(s,3H),2.08–1.98(m,6H),1.61(s,2H),1.33–1.27(m,28H),0.93-0.80(m,15H).
[0433] Example 64: Preparation of 3-((3-decyltridecyl-2-enoyl)oxy)-2-((((3-(dimethylamino)-2,2-dimethylpropyloxy)carbonyl)oxy)methyl)propyl (9Z,12Z)-octadec-9,12-dienoate (CPL-322)
[0434] A mixture of 3-((E)-3-decyltridec-2-enoate)-2-(hydroxymethyl)propanyl-(9Z,12Z)-octa-9,12-dienoate (190 mg, 0.2707 mmol, 1.0 equiv), 3-dimethylamino-2,2-dimethyl-1-propanol (71 mg, 0.5413 mmol, 2.0 equiv), pyridine (214 mg, 2.707 mmol, 10.0 equiv), and triphosgene (32 mg, 0.1083 mmol, 0.4 equiv) in dichloromethane (6 mL) was stirred at room temperature for 16 hours. 40 mL of water was added, and the mixture was extracted three times with 20 mL of dichloromethane. The organic phase was washed three times with 40 mL of sodium chloride solution, filtered, and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to give the target CPL-322 (39.69 mg, 17% yield) as a colorless oil.
[0435] LC / MS (ESI) m / z: 860.8 (M+H) + .
[0436] 1HNMR (400MHz, CDCl3) δ5.53 (s, 1H), 5.35–5.22 (m, 4H), 4.10 (ddd, J = 14.5 ,11.9,7.4Hz,6H),3.88(s,2H),2.70(t,J=6.5Hz,2H),2.58–2.45(m,2H), 2.38(dt,J=11.8,5.9Hz,1H),2.29–2.16(m,8H),2.02(ddd,J=20.3,14.5, 7.3Hz, 8H), 1.37 (d, J = 7.4Hz, 2H), 1.26–1.17 (m, 46H), 0.85–0.79 (m, 15H).
[0437] Example 65: Preparation of 3-((((1-methylpyrrolidin-3-yl)methoxy)carbonyl)oxy)-2-((((E)-3-propylnon-2-enoyl)oxy)methyl)propyl (9Z,12Z)-octadec-9,12-dienoate (CPL-324)
[0438] 3-((E)-3-Propanylnon-2-enoate)-2-(hydroxymethyl)propanyl-(9Z,12Z)-octadec-9,12-dienoate (300 mg, 0.547 mmol, 1.0 equiv) and triphosgene (65 mg, 0.218 mmol, 0.4 equiv) were mixed in dichloromethane (6 mL). 4-Dimethylaminopyridine (133 mg, 1.094 mmol, 2.0 equiv) was added dropwise at 0°C under nitrogen protection and stirred for 20 minutes. 1-Methyl-3-pyrrolidinemethanol (126 mg, 1.094 mmol, 2.0 equiv) was added dropwise and stirred at room temperature overnight. 15 mL of ice water was added and the mixture was extracted three times with 20 mL of dichloromethane. The organic phase was washed three times with 20 mL of sodium chloride solution, filtered, and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to give the target CPL-324 (112 mg, 29.7% yield) as a colorless oil.
[0439] LC / MS (ESI) m / z: 690.6 (M+H) + .
[0440] 1H NMR (400MHz, CDCL3) δ5.61 (d, J=5.2Hz, 1H), 5.39-5.31 (m, 4H), 4.22-4.01 (m, 8H),2.78(t,J=6.8Hz,2H),2.66-2.64(m,1H),2.59-2.51(m,5H),2.45-2.42(m ,1H),2.35(s,3H),2.32(t,J=7.6Hz,2H),2.15-2.10(m,2H),2.07-2.00(m,5H) ,1.62-1.60(m,2H),1.52-1.42(m,4H),1.37-1.25(m,22H),0.96-0.85(m,9H).
[0441] Example 66: Preparation of 3-(((E)-3-butylundec-2-enoyl)oxy)-2-(((((1-methylpyrrolidin-3-yl)methoxy)carbonyl)oxy)methyl)propyl (9Z,12Z)-octadec-9,12-dienoate (CPL-329)
[0442] 3-((E)-3-Butyl undec-2-enoate)-2-(hydroxymethyl)propanyl-(9Z,12Z)-octa-9,12-dienoate (200 mg, 0.339 mmol, 1.0 equiv) and triphosgene (40 mg, 0.135 mmol, 0.4 equiv) were mixed in dichloromethane (5 mL). 4-Dimethylaminopyridine (82 mg, 0.678 mmol, 2.0 equiv) was added dropwise at 0°C under nitrogen protection, and the mixture was stirred for 20 minutes. 1-Methyl-3-pyrrolidinemethanol (78 mg, 0.678 mmol, 2.0 equiv) was added dropwise, and the mixture was stirred at room temperature overnight. 15 mL of ice water was added, and the mixture was extracted three times with 20 mL of dichloromethane. The organic phase was washed three times with 20 mL of sodium chloride solution, filtered, and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to give the target CPL-329 (57 mg, 22.9% yield) as a colorless oil.
[0443] LC / MS (ESI) m / z: 732.1 (M+H) + .
[0444] 1H NMR (400MHz, CDCL3) δ5.60(s,1H),5.40-5.31(m,4H),4.22-4.12(m,8H),2.90-2.65(m,7H),2.59-2.55(m,2H),2.48-2.40(m,1H),2. 32-2.20(m,3H),2.16-2.11(m,2H),2.07-2.02(m,6H),1.90-1.78(m,2H),1.62-1.59(m,2H),1.46-1.26(m,30H),0.93-0.83(m,9H).
[0445] Example 67: Preparation of 3-(((E)-3-butyldec-2-enoyl)oxy)-2-(((((1-methylpyrrolidin-3-yl)methoxy)carbonyl)oxy)methyl)propyl (9Z,12Z)-octadec-9,12-dienoate (CPL-338)
[0446] A mixture of 3-((E)-3-butanedec-2-enoate)-2-(hydroxymethyl)propane-(9Z,12Z)-octa-9,12-dienoate (200 mg, 0.35 mmol, 1.0 equiv), pyridine (276.5 mg, 3.5 mmol, 10.0 equiv) and triphosgene (41.16 mg, 0.14 mmol, 0.4 equiv) in dichloromethane (2 mL) was stirred at 0°C for 30 minutes. 1-Methyl-3-pyrrolidinemethanol (115.17 mg, 1.04 mmol, 3.0 equiv) was added and stirred at room temperature for 16 hours. 30 mL of water was added and extracted three times with 20 mL of dichloromethane. The organic phase was washed three times with 30 mL of sodium chloride solution, filtered and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to give the target CPL-338 (36.08 mg, 14% yield) as a colorless oil.
[0447] LCMS (ESI) m / z: 718.07 (M+H) + .
[0448] 1H NMR(400MHz, CDCl3)δ5.61(s,1H),5.36(dt,J=12.4,6.8Hz,4H),4.26–4.01(m,8H),2.77(t,J=6.5Hz,2H),2.59(dd,J=29.1,20.1Hz ,6H),2.47–2.40(m,1H),2.34(d,J=11.0Hz,4H),2.18–2.10(m,2H),2.07–2.01(m,4H),1.28(d,J=18.0Hz,34H),0.96–0.89(m,9H).
[0449] Example 68: Preparation of 3-((((1-methylpyrrolidin-3-yl)methoxy)carbonyl)oxy)-2-((((Z)-3-octyltridec-2-enoyl)oxy)methyl)propyl (9Z,12Z)-octadec-9,12-dienoate (CPL-343)
[0450] A mixture of 3-((E)-3-octyl tridec-2-enoate)-2-(hydroxymethyl)propanyl-(9Z,12Z)-octa-9,12-dienoate (190 mg, 0.2819 mmol, 1.0 equiv), 1-methyl-3-pyrrolidinemethanol (65 mg, 0.5638 mmol, 2.0 equiv), pyridine (223 mg, 2.819 mmol, 10.0 equiv), and triphosgene (33 mg, 0.1128 mmol, 0.4 equiv) in dichloromethane (8 mL) was stirred at room temperature for 16 hours. 40 mL of water was added, and the mixture was extracted three times with 20 mL of dichloromethane. The organic phase was washed three times with 40 mL of sodium chloride solution, filtered, and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to give the target CPL-343 (31.78 mg, 14% yield) as a colorless oil.
[0451] LC / MS (ESI) m / z: 816.6 (M+H) + .
[0452] 1HNMR (400MHz, CDCl3) δ5.53 (s, 1H), 5.35–5.22 (m, 4H), 4.17–3.93 (m, 8H), 2.70 (t, J = 6.1Hz, 2H), 2.50 (dd, J = 14.6, 6.5Hz, 5H), 2.41–2.33 (m, 1H),2.25(dd,J=17.3,9.8Hz,6H),2.10–2.02(m,2H),1.98(dd,J=13.5,6.5Hz,5H),1.40–1.34(m,4H),1.25–1.17(m,42H),0.82–0.79(m,9H).
[0453] Example 69: Preparation of 3-(((E)-3-butylundec-2-enoyl)oxy)-2-(((((1-methylpyrrolidin-3-yl)methoxy)carbonyl)oxy)methyl)propyl (9Z,12Z)-octadec-9,12-dienoate (CPL-348)
[0454] 3-((E)-3-Propanyl tridec-2-enoate)-2-(hydroxymethyl)propanyl-(9Z,12Z)-octa-9,12-dienoate (250 mg, 0.414 mmol, 1.0 equiv) and triphosgene (49 mg, 0.165 mmol, 0.4 equiv) were mixed in dichloromethane (6 mL). A solution of 4-dimethylaminopyridine (101 mg, 0.828 mmol, 2.0 equiv) in 0.5 mL of dichloromethane was added dropwise at 0°C under nitrogen protection, and the mixture was stirred for 20 minutes. 3-Dimethylamino-2,2-dimethyl-1-propanol (131 mg, 0.828 mmol, 2.0 equiv) was added dropwise, and the mixture was stirred at room temperature overnight. 15 mL of ice water was added, and the mixture was extracted three times with 20 mL of dichloromethane. The organic phase was washed three times with 20 mL of sodium chloride solution, filtered, and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to give target CPL-348 (151 mg, 46.1% yield) as a colorless oil.
[0455] LC / MS (ESI) m / z: 791.2 (M+H) + .
[0456] 1H NMR(400MHz,CDCL3)δ5.62(d,J=5.6Hz,1H),5.41-5.29(m,4H),4.21-4.12(m ,6H),3.91(s,2H),2.78(t,J=6.8Hz,2H),2.58-2.54(m,2H),2.52-2.41(m,5H ),2.32(t,J=7.6Hz,2H),2.23(s,2H),2.14-2.10(m,2H),2.07-2.00(m,4H),1 .62-1.60(m,2H),1.54-1.42(m,4H),1.39-1.26(m,28H),0.97-0.85(m,21H).
[0457] Example 70: Preparation of 3-(((E)-3-butylundec-2-enoyl)oxy)-2-(((((diethylamino)-2,2-dimethylpropyloxy)carbonyl)oxy)methyl)propyl (9Z,12Z)-octadec-9,12-dienoate (CPL-351)
[0458] 3-((E)-3-Butyl undec-2-enoate)-2-(hydroxymethyl)propanyl-(9Z,12Z)-octa-9,12-dienoate (200 mg, 0.339 mmol, 1.0 equiv) and triphosgene (40 mg, 0.135 mmol, 0.4 equiv) were mixed in dichloromethane (5 mL). 4-Dimethylaminopyridine (82 mg, 0.678 mmol, 2.0 equiv) was added dropwise at 0°C under nitrogen protection, and the mixture was stirred for 20 minutes. 3-Dimethylamino-2,2-dimethyl-1-propanol (107 mg, 0.678 mmol, 2.0 equiv) was added dropwise, and the mixture was stirred at room temperature overnight. 15 mL of ice water was added, and the mixture was extracted three times with 20 mL of dichloromethane. The organic phase was washed three times with 20 mL of sodium chloride solution, filtered, and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to give the target CPL-351 (60 mg, 22.8% yield) as a colorless oil.
[0459] LC / MS (ESI) m / z: 776.7 (M+H) + .
[0460] 1H NMR (400MHz, CDCL3) δ5.60(s,1H),5.41-5.29(m,4H),4.21-4.12(m,6H),3.91(s,2H),2.78(t,J=6.4Hz,2H),2.59-2.41(m,6H),2.32( t,J=7.6Hz,2H),2.26-2.20(m,1H),2.15-2.12(m,2H),2.07-2.00(m,6H),1.62-1.60(m,2H),1.46-1.26(m,35H),0.96-0.87(m,15H).
[0461] Example 71: Preparation of 3-(((3-(diethylamino)-2,2-dimethylpropyloxy)carbonyl)oxy)-2-((((E)-3-pentylundecan-2-enoyl)oxy)methyl)propyl (9Z,12Z)-octadec-9,12-dienoate (CPL-355)
[0462] A mixture of 3-((E)-3-pentyl undec-2-enoate)-2-(hydroxymethyl)propanyl-(9Z,12Z)-octa-9,12-dienoate (200 mg, 0.3306 mmol, 1.0 equiv), 3-dimethylamino-2,2-dimethyl-1-propanol (157.97 mg, 0.9918 mmol, 3.0 equiv), pyridine (261.51 mg, 3.31 mmol, 10.0 equiv), and triphosgene (39.12 mg, 0.1322 mmol, 0.4 equiv) in dichloromethane (5 mL) was stirred at room temperature for 16 hours. 40 mL of water was added, and the mixture was extracted three times with 20 mL of dichloromethane. The organic phase was washed three times with 40 mL of sodium chloride solution, filtered, and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to give the target CPL-355 (114.7 mg, 43.9% yield) as a colorless oil.
[0463] LC / MS (ESI) m / z: 790.8 (M+H) + .
[0464] 1HNMR (400MHz, CDCl3) δ5.60 (s, 1H), 5.35 (d, J = 6.4Hz, 4H), 4.22–4.12 (m, 6 H),3.92(s,2H),2.77(t,J=5.8Hz,2H),2.62–2.54(m,2H),2.48(d,J=6.8Hz ,2H),2.30(t,J=7.8Hz,2H),2.24(s,2H),2.16–2.11(m,2H),2.04(s,4H),1 .56(s,6H),1.44(s,6H),1.25(s,32H),0.94(d,J=7.8Hz,6H),0.88(s,8H).
[0465] Example 72: Preparation of 3-(((3-(diethylamino)-2,2-dimethylpropyloxy)carbonyl)oxy)-2-((((E)-3-heptyltridec-2-enoyl)oxy)methyl)propyl (9Z,12Z)-octadec-9,12-dienoate (CPL-363)
[0466] A mixture of 3-((E)-3-heptyl tridec-2-enoate)-2-(hydroxymethyl)propanyl-(9Z,12Z)-octa-9,12-dienoate (200 mg, 0.303 mmol, 1.0 equiv), pyridine (239.67 mg, 3.03 mmol, 10.0 equiv) and triphosgene (35.9 mg, 0.121 mmol, 0.4 equiv) in dichloromethane (5 mL) was stirred at 0°C for 30 minutes. 3-Dimethylamino-2,2-dimethyl-1-propanol (96.45 mg, 0.606 mmol, 2.0 equiv) was added and stirred at room temperature for 16 hours. 30 mL of water was added and the mixture was extracted three times with 20 mL of dichloromethane. The organic phase was washed three times with 30 mL of sodium chloride solution, filtered and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to give target CPL-363 (42.5 mg, 16.57% yield) as a colorless oil.
[0467] LCMS (ESI) m / z: 846.71 (M+H) + .
[0468] 1H NMR(400MHz,Chloroform-d)δ5.60(s,1H),5.42–5.29(m,4H),4.23–4.14(m ,6H),3.92(s,2H),2.77(t,J=6.5Hz,2H),2.61–2.54(m,2H),2.53–2.41(m,5 H),2.30(t,J=7.6Hz,2H),2.24(s,2H),2.17–2.10(m,2H),2.05(m,4H),1.4 4(d,J=7.4Hz,2H),1.39–1.25(m,40H),0.95(t,J=7.1Hz,6H),0.88(m,15H).
[0469] Example 73: Preparation of 3-(((Z)-3-butylnon-2-enoyl)oxy)-2-(((((1-methylpiperidin-3-yl)methoxy)carbonyl)oxy)methyl)propyl (9Z,12Z)-octadec-9,12-dienoate (CPL-372)
[0470] A mixture of 3-((E)-3-butylnon-2-enoate)-2-(hydroxymethyl)propanyl-(9Z,12Z)-octa-9,12-dienoate (150 mg, 0.267 mmol, 1.0 equiv), pyridine (212.2 mg, 2.67 mmol, 10.0 equiv), and triphosgene (31.69 mg, 0.107 mmol, 0.4 equiv) in dichloromethane (2 mL) was stirred at 0°C for 30 minutes. 1-Methylpiperidine-3-methanol (68.82 mg, 0.533 mmol, 2.0 equiv) was added and stirred at room temperature for 16 hours. 30 mL of water was added and the mixture was extracted three times with 20 mL of dichloromethane. The organic phase was washed three times with 30 mL of sodium chloride solution, filtered, and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to give target CPL-372 (40.26 mg, 21.01% yield) as a colorless oil.
[0471] LCMS (ESI) m / z: 718.55 (M+H) + .
[0472] 1H NMR(400MHz,Chloroform-d)δ5.61(s,1H),5.43–5.28(m,4H),4.24–4.11(m,6H),4.06 (m,1H),3.96(m,1H),2.87(d,J=11.1Hz,1H),2.77(t,J=6.6Hz,2H),2.58(t,J=6.5Hz, 1H),2.44(m,1H),2.30(d,J=6.9Hz,4H),2.17(s,7H),2.13(d,J=8.2Hz,2H),2.05(m,5 H),1.72(d,J=11.6Hz,3H),1.46–1.40(m,3H),1.38–1.25(m,24H),0.93–0.86(m,9H).
[0473] Example 74: Preparation of 3-((((1-methylpiperidin-3-yl)methoxy)carbonyl)oxy)-2-(((E)-3-pentylundecanyloxy)methyl)propyl (9Z,12Z)-octadec-9,12-dienoate (CPL-377)
[0474] A mixture of 3-((E)-3-pentyl undec-2-enoate)-2-(hydroxymethyl)propanyl-(9Z,12Z)-octa-9,12-dienoate (200 mg, 0.33 mmol, 1.0 equiv), pyridine (261 mg, 3.3 mmol, 10.0 equiv), and triphosgene (40 mg, 0.13 mmol, 0.4 equiv) in dichloromethane (3 mL) was stirred at 0°C for 30 minutes. A solution of 1-methylpiperidine-3-methanol (185 mg, 0.99 mmol, 3.0 equiv) in dichloromethane (1 mL) was added and stirred at room temperature for 16 hours. 30 mL of water was added and the mixture was extracted three times with 20 mL of dichloromethane. The organic phase was washed three times with 30 mL of sodium chloride solution, filtered, and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to give the target CPL-377 (22 mg, 8% yield) as a colorless oil.
[0475] LC / MS (ESI) m / z: 760.6 (M+H) + .
[0476] 1H NMR(400MHz, CDCl3)δ5.61(s,1H),5.44–5.27(m,4H),4.25–4.11(m,6H),4.11– 4.03(m,1H),3.99–3.89(m,1H),2.88–2.71(m,4H),2.61–2.55(m,2H),2.48–2. 40(m,1H),2.35–2.30(m,2H),2.26(s,3H),2.18–2.10(m,2H),2.09–1.97(m,4H ),1.77–1.66(m,4H),1.45–1.28(m,35H),1.05–0.99(m,2H),0.94–0.85(m,9H).
[0477] Example 75: Preparation of 3-((((1-methylpiperidin-3-yl)methoxy)carbonyl)oxy)-2-((((E)-3-pentyltridec-2-enoyl)oxy)methyl)propyl (9Z,12Z)-octadec-9,12-dienoate (CPL-378)
[0478] A mixture of 3-((E)-3-pentyl tridec-2-enoate)-2-(hydroxymethyl)propanyl-(9Z,12Z)-octa-9,12-dienoate (200 mg, 0.31 mmol, 1.0 equiv), pyridine (250 mg, 3.1 mmol, 10.0 equiv) and triphosgene (38 mg, 0.12 mmol, 0.4 equiv) in dichloromethane (3 mL) was stirred at 0°C for 30 minutes. A solution of 1-methylpiperidine-3-methanol (125 mg, 0.95 mmol, 3.0 equiv) in dichloromethane (1 mL) was added and stirred at room temperature for 16 hours. 10 mL of water was added and the mixture was extracted three times with 10 mL of dichloromethane. The organic phase was washed three times with 20 mL of sodium chloride solution, filtered and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to give target CPL-378 (81 mg, 32% yield) as a colorless oil.
[0479] LC / MS (ESI) m / z: 788.6 (M+H) + .
[0480] 1H NMR(400MHz, CDCl3)δ5.60(s,1H),5.44–5.28(m,4H),4.28–4.11(m,6H),4.10– 3.89(m,2H),2.88–2.69(m,4H),2.64–2.54(m,2H),2.48–2.42(m,1H),2.36–2. 29(m,2H),2.27(s,3H),2.18–2.10(m,2H),2.09–1.96(m,5H),1.96–1.85(m,1H ),1.77–1.66(m,4H),1.45–1.22(m,37H),1.08–0.93(m,2H),0.92–0.83(m,9H).
[0481] Example 76: Preparation of 3-(((E)-3-hexyltridec-2-enoyl)oxy)-2-(((((1-methylpiperidin-3-yl)methoxy)carbonyl)oxy)methyl)propyl (9Z,12Z)-octadecane-9,12-dienoate (CPL-381)
[0482] A mixture of 3-((E)-3-hexyltridec-2-enoate)-2-(hydroxymethyl)propane-(9Z,12Z)-octadec-9,12-dienoate (150 mg, 0.23 mmol, 1.0 equiv), pyridine (184 mg, 2.3 mmol, 10.0 equiv), and triphosgene (28 mg, 0.09 mmol, 0.4 equiv) in dichloromethane (3 mL) was stirred at 0°C for 30 minutes. A solution of 1-methylpiperidine-3-methanol (92 mg, 0.69 mmol, 3.0 equiv) in dichloromethane (1 mL) was added and stirred at room temperature for 16 hours. 10 mL of water was added and the mixture was extracted three times with 10 mL of dichloromethane. The organic phase was washed three times with 20 mL of sodium chloride solution, filtered, and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to give the target CPL-381 (52 mg, 28% yield) as a colorless oil.
[0483] LC / MS (ESI) m / z: 802.6 (M+H) + .
[0484] 1H NMR(400MHz, CDCl3)δ5.60(s,1H),5.44–5.28(m,4H),4.27–4.19(m,2H),4.19– 4.11(m,4H),4.09–4.01(m,1H),4.01–3.92(m,1H),2.88–2.70(m,4H),2.62–2.5 3(m,2H),2.51–2.39(m,1H),2.38–2.28(m,2H),2.28(s,3H),2.16–2.11(m,2H) ,2.08–1.86(m,6H),1.80–1.66(m,4H),1.46–1.26(m,38H),1.07–0.85(m,12H).
[0485] Example 77: Preparation of 3-(((2-(dimethylamino)ethoxy)carbonyl)oxy)-2-((((E)-3-hexyldecan-2-enoyl)oxy)methyl)propyl (9Z,12Z)-octadec-9,12-dienoate (CPL-383)
[0486] A mixture of 3-((E)-3-hexyldec-2-enoate)-2-(hydroxymethyl)propanyl-(9Z,12Z)-octa-9,12-dienoate (200 mg, 0.33 mmol, 1.0 equiv), pyridine (260.7 mg, 3.3 mmol, 10.0 equiv) and triphosgene (40 mg, 0.13 mmol, 0.4 equiv) in dichloromethane (2 mL) was stirred at 0°C for 30 minutes. 1-Methylpiperidine-3-methanol (129 mg, 1.04 mmol, 3.0 equiv) was added and stirred at room temperature for 16 hours. 30 mL of water was added and extracted three times with 20 mL of dichloromethane. The organic phase was washed three times with 30 mL of sodium chloride solution, filtered and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to give the target CPL-383 (25.83 mg, 6% yield) as a colorless oil.
[0487] LCMS (ESI) m / z: 760.59 (M+H) + .
[0488] 1H NMR(400MHz, CDCl3)δ5.60(s,1H),5.44–5.25(m,4H),4.17-3.93(m,8H),2.89–2.67(m,4H),2.61–2.54(m,1H),2. 49–2.39(m,1H),2.33–2.24(m,5H),2.19–1.80(m,10H),1.78–1.66(m,4H),1.32–1.25(m,32H),0.91-0.85(m,9H)
[0489] Example 78: Preparation of 3-(((Z)-3-butylnon-2-enoyl)oxy)-2-((((3-(4-methylpiperazin-1-yl)propyloxy)carbonyl)oxy)methyl)propyl (9Z,12Z)-octadec-9,12-dienoate (CPL-394)
[0490] A mixture of 3-((E)-3-butanenon-2-enoate)-2-(hydroxymethyl)propane-(9Z,12Z)-octa-9,12-dienoate (150 mg, 0.267 mmol, 1.0 equiv), pyridine (212.2 mg, 2.67 mmol, 10.0 equiv) and triphosgene (31.69 mg, 0.107 mmol, 0.4 equiv) in dichloromethane (2 mL) was stirred at 0°C for 30 minutes. A solution of 1-(3-hydroxypropyl)-4-methylpiperazine (69.89 mg, 0.533 mmol, 2.0 equiv) in dichloromethane (1 mL) was added and stirred at room temperature for 16 hours. 30 mL of water was added and the mixture was extracted three times with 20 mL of dichloromethane. The organic phase was washed three times with 30 mL of sodium chloride solution, filtered and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to give the target CPL-394 (30.22 mg, 15.2% yield) as a colorless oil.
[0491] LCMS (ESI) m / z: 747.58 (M+H) + .
[0492] 1H NMR(400MHz,Chloroform-d)δ5.61(s,1H),5.42–5.28(m,4H),4.25–4.11(m,8H),2.77(t,J=6.3Hz,2H),2.63–2.39(m,11H ),2.35–2.27(m,5H),2.14(t,J=7.6Hz,2H),2.05(m,4H),1.87(m,2H),1.48–1.40(m,4H),1.40–1.22(m,26H),0.89(m,9H).
[0493] Example 79: Preparation of 3-(((3-(4-methylpiperazin-1-yl)propyloxy)carbonyl)oxy)-2-((((E)-3-pentylnon-2-enoyl)oxy)methyl)propyl (9Z,12Z)-octadec-9,12-dienoate (CPL-398)
[0494] A mixture of 3-((E)-3-pentylnon-2-enoate)-2-(hydroxymethyl)propanyl-(9Z,12Z)-octa-9,12-dienoate (200 mg, 0.3472 mmol, 1.0 equiv), 1-(3-hydroxypropyl)-4-methylpiperazine (110 mg, 0.6944 mmol, 2.0 equiv), pyridine (274 mg, 3.472 mmol, 10.0 equiv), and triphosgene (41 mg, 0.1389 mmol, 0.4 equiv) in dichloromethane (8 mL) was stirred at room temperature for 16 hours. 40 mL of water was added, and the mixture was extracted three times with 20 mL of dichloromethane. The organic phase was washed three times with 40 mL of sodium chloride solution, filtered, and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to give the target CPL-398 (25.79 mg, 9.8% yield) as a colorless oil.
[0495] LC / MS (ESI) m / z: 761.6 (M+H) + .
[0496] 1HNMR(400MHz, CDCl3)δ5.54(s,1H),5.33–5.22(m,4H),4.15–4.07(m,8H ),2.70(t,J=6.6Hz,2H),2.53–2.48(m,2H),2.43–2.31(m,8H),2.27–2.20 (m,6H),2.09–2.03(m,2H),1.98(q,J=6.4Hz,4H),1.79(dd,J=14.2,6.8Hz ,2H),1.39–1.34(m,4H),1.24–1.18(m,28H),0.82(dd,J=6.9,4.4Hz,9H).
[0497] Example 80: Preparation of 3-(((E)-3-heptyltridec-2-enoyl)oxy)-2-((((3-(4-methylpiperazin-1-yl)propyloxy)carbonyl)oxy)methyl)propyl (9Z,12Z)-octadeca-9,12-dienoate (CPL-407)
[0498] A mixture of 3-((E)-3-heptyl tridec-2-enoate)-2-(hydroxymethyl)propanyl-(9Z,12Z)-octa-9,12-dienoate (200 mg, 0.303 mmol, 1.0 equiv), pyridine (239.67 mg, 3.03 mmol, 10.0 equiv) and triphosgene (35.9 mg, 0.121 mmol, 0.4 equiv) in dichloromethane (5 mL) was stirred at 0°C for 30 minutes. 1-(3-hydroxypropyl)-4-methylpiperazine (95.83 mg, 0.606 mmol, 2.0 equiv) was added and stirred at room temperature for 16 hours. 30 mL of water was added and extracted three times with 20 mL of dichloromethane. The organic phase was washed three times with 30 mL of sodium chloride solution, filtered and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to give the target CPL-407 (21.72 mg, 8.48% yield) as a colorless oil.
[0499] LCMS (ESI) m / z: 845.69 (M+H) + .
[0500] 1H NMR(400MHz,Chloroform-d)δ5.60(s,1H),5.41–5.30(m,4H),4.22–4.14(m,8H),2.77(t,J=6.5Hz,2H),2.57(t,J=7.8Hz,7H),2.4 5(m,4H),2.34(d,J=10.7Hz,3H),2.29(d,J=7.6Hz,2H),2.16–2.10(m,2H),2.05(m,4H),1.87(m,2H),1.44(d,J=7.3Hz,4H),1.36– 1.24(m,40H),0.91–0.86(m,9H).
[0501] Example 81: Preparation of 3-(((3-(4-methylpiperazin-1-yl)propyloxy)carbonyl)oxy)-2-((((Z)-3-octyltridec-2-enoyl)oxy)methyl)propyl (9Z,12Z)-octadecane-9,12-dienoate (CPL-409)
[0502] A mixture of 3-((E)-3-octyl tridec-2-enoate)-2-(hydroxymethyl)propanyl-(9Z,12Z)-octa-9,12-dienoate (190 mg, 0.2819 mmol, 1.0 equiv), 1-(3-hydroxypropyl)-4-methylpiperazine (89 mg, 0.5638 mmol, 2.0 equiv), pyridine (223 mg, 2.819 mmol, 10.0 equiv), and triphosgene (33 mg, 0.1128 mmol, 0.4 equiv) in dichloromethane (8 mL) was stirred at room temperature for 16 hours. 40 mL of water was added, and the mixture was extracted three times with 20 mL of dichloromethane. The organic phase was washed three times with 40 mL of sodium chloride solution, filtered, and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to give the target CPL-409 (23.57 mg, 10% yield) as a colorless oil.
[0503] LC / MS (ESI) m / z: 859.7 (M+H) + .
[0504] 1H NMR(400MHz, CDCl3)δ5.53(s,1H),5.34–5.22(m,4H),4.18–4.03(m,8H),2.7 0(t,J=6.5Hz,2H),2.53–2.48(m,4H),2.38(dd,J=14.3,6.7Hz,4H),2.28–2. 21(m,5H),2.10–2.03(m,2H),1.98(q,J=6.8Hz,4H),1.83–1.74(m,2H),1.58 –1.49(m,3H),1.37(d,J=7.9Hz,4H),1.25–1.17(m,42H),0.83–0.79(m,9H).
[0505] Example 82: Preparation of 3-(((Z)-3-butylnon-2-enoyl)oxy)-2-((((3-(piperidin-1-yl)propyloxy)carbonyl)oxy)methyl)propyl (9Z,12Z)-octadec-9,12-dienoate (CPL-416)
[0506] A mixture of 3-((E)-3-butanenon-2-enoate)-2-(hydroxymethyl)propane-(9Z,12Z)-octa-9,12-dienoate (150 mg, 0.267 mmol, 1.0 equiv), pyridine (212.12 mg, 2.67 mmol, 10.0 equiv) and triphosgene (31.69 mg, 0.107 mmol, 0.4 equiv) in dichloromethane (2 mL) was stirred at 0°C for 30 minutes. 1-Piperidinepropanol (76.28 mg, 0.533 mmol, 2.0 equiv) was added and stirred at room temperature for 16 hours. 30 mL of water was added and the mixture was extracted three times with 20 mL of dichloromethane. The organic phase was washed three times with 30 mL of sodium chloride solution, filtered and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to give the target CPL-416 (29.03 mg, 14.9% yield) as a colorless oil.
[0507] LCMS (ESI) m / z: 732.57 (M+H) + .
[0508] 1H NMR (400MHz, Chloroform-d) δ5.61 (s, 1H), 5.35 (m, 4H), 4.24–4.11 (m, 8H), 2.77 (t, J = 6.5Hz, 2H), 2.60–2.56 (m, 1H), 2.51–2. 35(m,6H),2.30(t,J=7.6Hz,2H),2.14(m,2H),2.05(q,J=6.9Hz,4H),1.90(t,J=7.2Hz,2H),1.58–1.19(m,36H),0.89(m,9H).
[0509] Example 83: Preparation of 3-(((E)-3-pentylundecan-2-enoyl)oxy)-2-((((3-(piperidin-1-yl)propyloxy)carbonyl)oxy)methyl)propyl (9Z,12Z)-octadec-9,12-dienoate (CPL-421)
[0510] A mixture of 3-((E)-3-pentyl undec-2-enoate)-2-(hydroxymethyl)propanyl-(9Z,12Z)-octa-9,12-dienoate (200 mg, 0.3306 mmol, 1.0 equiv), 1-piperidinylpropanol (142.06 mg, 0.9918 mmol, 3.0 equiv), pyridine (261.51 mg, 3.31 mmol, 10.0 equiv), and triphosgene (39.24 mg, 0.1322 mmol, 0.4 equiv) in dichloromethane (5 mL) was stirred at room temperature for 16 hours. 40 mL of water was added, and the mixture was extracted three times with 20 mL of dichloromethane. The organic phase was washed three times with 40 mL of sodium chloride solution, filtered, and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to give the target CPL-421 (86.45 mg, 33.78% yield) as a colorless oil.
[0511] LC / MS (ESI) m / z: 774.6 (M+H) + .
[0512] 1H NMR(400MHz, CDCl3)δ5.60(s,1H),5.35(qd,J=8.4,2.7Hz,4H),4.21–4.14(m,8H),2.76(d,J=6.8Hz,2H),2.60 –2.53(m,2H),2.34(t,J=15.8Hz,6H),2.13–2.03(m,6H),1.88(s,2H),1.54–1.27(m,42H),0.91–0.87(m,10H).
[0513] Example 84: Preparation of 3-(((E)-3-heptylundecan-2-enoyl)oxy)-2-((((3-(piperidin-1-yl)propyloxy)carbonyl)oxy)methyl)propyl (9Z,12Z)-octadec-9,12-dienoate (CPL-428)
[0514] A mixture of 3-((E)-3-heptyl undec-2-enoate)-2-(hydroxymethyl)propanyl-(9Z,12Z)-octa-9,12-dienoate (200 mg, 0.32 mmol, 1.0 equiv), pyridine (253.12 mg, 3.2 mmol, 10.0 equiv), and triphosgene (35.60 mg, 0.12 mmol, 0.4 equiv) in dichloromethane (3 mL) was stirred at 0°C for 30 minutes. 1-Piperidinepropanol (90.23 mg, 0.63 mmol, 2.0 equiv) was added and stirred at room temperature for 16 hours. 30 mL of water was added and the mixture was extracted three times with 20 mL of dichloromethane. The organic phase was washed three times with 30 mL of sodium chloride solution, filtered, and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to give target CPL-428 (33.21 mg, 12.93% yield) as a colorless oil.
[0515] LCMS (ESI) m / z: 803.7 (M+H) + .
[0516] 1H NMR(400MHz, CDCl3)δ5.60(d,J=5.8Hz,1H),5.42–5.28(m,4H),4.28–4.03(m,8H),2.77(t,J=6.4Hz,2H),2.63–2.54(m,2H),2.54–2.34(m,6H), 2.34–2.19(m,3H),2.17–2.09(m,2H),2.07–2.01(m,4H),1.84(ddd,J=6 2.8, 46.7, 40.0Hz, 4H), 1.60–1.20 (m, 42H), 0.88 (dd, J=6.9, 4.2Hz, 9H).
[0517] Example 85: Preparation of 3-((((1-ethylpiperidin-4-yl)methoxy)carbonyl)oxy)-2-((((E)-3-hexyldecan-2-enoyl)oxy)methyl)propyl (9Z,12Z)-octadec-9,12-dienoate (CPL-449)
[0518] A mixture of 3-((E)-3-hexyldec-2-enoate)-2-(hydroxymethyl)propanyl-(9Z,12Z)-octa-9,12-dienoate (200 mg, 0.33 mmol, 1.0 equiv), pyridine (260.7 mg, 3.3 mmol, 10.0 equiv) and triphosgene (40 mg, 0.13 mmol, 0.4 equiv) in dichloromethane (3 mL) was stirred at 0°C for 30 minutes. 1-Piperidinepropanol (143.23 mg, 1.04 mmol, 3.0 equiv) was added and stirred at room temperature for 16 hours. 30 mL of water was added and the mixture was extracted three times with 20 mL of dichloromethane. The organic phase was washed three times with 30 mL of sodium chloride solution, filtered and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to give the target CPL-449 (50.72 mg, 39% yield) as a colorless oil.
[0519] LCMS (ESI) m / z: 774.18 (M+H) + .
[0520] 1H NMR (400MHz, CDCl3) δ5.60 (s, 1H), 5.41–5.26 (m, 4H), 4.22–4.14 (m, 6H), 3.98 (d, J = 6. 4Hz,2H),2.96(d,J=14.0Hz,2H),2.77(t,J=6.4Hz,2H),2.61–2.54(m,1H),2.47–2.37 (m,3H),2.29(d,J=7.7Hz,2H),2.16–1.98(m,6H),1.89(t,J=10.8Hz,2H),1.75(d,J=1 3.2Hz, 2H), 1.61 (s, 6H), 1.38–1.23 (m, 38H), 1.08 (t, J = 7.2Hz, 4H), 0.91-0.83 (m, 9H).
[0521] Example 86: Preparation of 3-(((1-ethylpiperidine-4-methoxy)carbonyl)oxy)-2-((((Z)-3-octyltridec-2-enoyl)oxy)methyl)propyl (9Z,12Z)-octadecane-9,12-dienoate (CPL-453)
[0522] A mixture of 3-((E)-3-octyl tridec-2-enoate)-2-(hydroxymethyl)propanyl-(9Z,12Z)-octa-9,12-dienoate (200 mg, 0.2967 mmol, 1.0 equiv), N-ethylpiperidine-1-methanol (85 mg, 0.5935 mmol, 3.0 equiv), pyridine (234 mg, 2.967 mmol, 10.0 equiv), and triphosgene (35 mg, 0.1187 mmol, 0.4 equiv) in dichloromethane (8 mL) was stirred at room temperature for 16 hours. 40 mL of water was added, and the mixture was extracted three times with 20 mL of dichloromethane. The organic phase was washed three times with 40 mL of sodium chloride solution, filtered, and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to give the target CPL-453 (44.16 mg, 18% yield) as a colorless oil.
[0523] LC / MS (ESI) m / z: 844.7 (M+H) + .
[0524] 1HNMR(400MHz, CDCl3)δ5.53(s,1H),5.35–5.22(m,4H),4.17–4.04(m,6H),3.92(d,J=6 .4Hz,2H),2.70(t,J=6.5Hz,2H),2.57–2.46(m,2H),2.37(dt,J=11.9,5.9Hz,2H),2.22 (dd,J=17.7,10.1Hz,2H),2.09–2.02(m,2H),1.98(dd,J=13.6,6.7Hz,4H),1.65(d,J=3 0.6Hz, 4H), 1.37 (d, J = 6.7Hz, 4H), 1.32–1.17 (m, 46H), 1.05 (s, 3H), 0.84–0.80 (m, 9H).
[0525] Example 87: Preparation of 3-((3-decyltridecyl-2-enoyl)oxy)-2-(((((1-ethylpiperidin-4-yl)methoxy)carbonyl)oxy)methyl)propyl (9Z,12Z)-octadec-9,12-dienoate (CPL-454)
[0526] A mixture of 3-((E)-3-decyltridec-2-enoate)-2-(hydroxymethyl)propanyl-(9Z,12Z)-octa-9,12-dienoate (200 mg, 0.2849 mmol, 1.0 equiv), N-ethylpiperidine-1-methanol (81 mg, 0.5698 mmol, 2.0 equiv), pyridine (225 mg, 2.849 mmol, 10.0 equiv), and triphosgene (34 mg, 0.1114 mmol, 0.4 equiv) in dichloromethane (6 mL) was stirred at room temperature for 16 hours. 40 mL of water was added, and the mixture was extracted three times with 20 mL of dichloromethane. The organic phase was washed three times with 40 mL of sodium chloride solution, filtered, and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to give the target CPL-454 (35.65 mg, 14% yield) as a colorless oil.
[0527] LC / MS (ESI) m / z: 873.7 (M+H) + .
[0528] 1HNMR (400MHz, CDCl3) δ5.53 (s, 1H), 5.35–5.21 (m, 4H), 4.19–4.04 (m, 6H), 3.92 (d, J= 6.5Hz,2H),2.70(t,J=6.5Hz,2H),2.56–2.46(m,2H),2.41–2.33(m,2H),2.22(dd,J=17 .5,9.9Hz,2H),2.09–2.03(m,2H),1.98(q,J=6.6Hz,4H),1.66(t,J=19.1Hz,4H),1.37 (dd,J=12.1,4.5Hz,4H),1.31–1.17(m,50H),1.03(t,J=6.9Hz,3H),0.83–0.79(m,9H).
[0529] Example 88: Preparation of 5-((5-(E)-3-butyltridec-2-enoyl)oxy)pentyl((3-hydroxypropyl)amino)pentyl(E)-3-propyl-2-tridecenoate (CPL-1092)
[0530] A mixture of compound (E)-5-bromopentyl-3-propanyl tridec-2-enoate (108 mg, 0.27 mmol, 1.1 equiv), 5-(3-hydroxypropylamino)-pentyl-3-butanyl tridec-2-enoate (100 mg, 0.24 mmol, 1.0 equiv), KCO (67 mg, 0.49 mmol, 2.0 equiv) and NaI (1.8 mg, 0.01 mmol, 0.05 equiv) in ACN (10 mL) was stirred at 85° C. for 16 hours. 40 mL of water was added and the mixture was extracted three times with 20 mL of ethyl acetate. The organic phase was washed three times with 40 mL of sodium chloride solution, filtered and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to give the target CPL-1092 (75.02 mg, 42.06% yield) as a colorless oil.
[0531] LC / MS (ESI) m / z: 734.7 (M+H)+.
[0532] 1H NMR (400MHz, CDCl3) δ5.55(s,2H),4.02-3.99(m,4H),3.74-3.71(m,2H),2.52-2.39(m ,10H),2.10-2.05(m,4H),1.63-1.56(m,6H),1.45-1.23(m,46H),0.87-0.81(m,12H).
[0533] Example 89: Preparation of 10-(((5-(E)-3-butyltridec-2-enoyl)oxy)pentyl)((3-hydroxypropyl)amino)decyl (E)-3-propyl-2-tridecenoate (CPL-1093)
[0534] A mixture of compound (E)-10-bromodecanyl-3-propanyl tridec-2-enoate (126 mg, 0.27 mmol, 1.1 equiv), 5-(3-hydroxypropylamino)-pentanyl-3-butanyl tridec-2-enoate (100 mg, 0.24 mmol, 1.0 equiv), KCO (67 mg, 0.49 mmol, 2.0 equiv) and NaI (1.8 mg, 0.01 mmol, 0.05 equiv) in ACN (10 mL) was stirred at 80° C. overnight. 40 mL of water was added and the mixture was extracted three times with 20 mL of ethyl acetate. The organic phase was washed three times with 40 mL of sodium chloride solution, filtered and dried over sodium sulfate. The mixture was concentrated and purified by preparative HPLC to give the target CPL-1093 (80.54 mg, 41.30% yield) as a colorless oil.
[0535] LC / MS (ESI) m / z: 805.7 (M+H)+.
[0536] 1H NMR (400MHz, CDCl3) δ5.55 (d, J=4.8Hz, 2H), 4.02-3.98 (m, 4H), 3.74-3.72 (m, 2H) ,2.64-2.41(m,10H),2.10-1.97(m,4H),1.65–1.25(m,62H),0.85–0.80(m,12H).
[0537] Test Case
[0538] The properties of the cationic lipids prepared as in the above examples were tested according to the following methods.
[0539] Preparation and characterization of lipid nanoparticles
[0540] According to the following steps, taking mRNA as an encapsulated drug as an example, lipid nanoparticles (LNPs) were prepared using the cationic lipids disclosed herein.
[0541] 1. The cationic lipid (50 mg / mL) prepared in the above examples of the present disclosure was dissolved in ethanol with cholesterol (20 mg / mL), DSPC (20 mg / mL) and DMG-PEG2000 (20 mg / mL), and the solution was placed in a 55°C metal thermostat bath to aid dissolution as needed to obtain a lipid mixture with the following molar composition: 1.5% DMG-PEG2000, 50% cationic lipid, 38.5% cholesterol and 10% DSPC.
[0542] 2. Dilute the mRNA encoding FFluc with 10 mM citrate buffer, pH 4.0, to prepare a 0.2 mg / mL mRNA solution.
[0543] 3. Use a syringe pump with a tee to mix the lipid mixture prepared in step 1 with the mRNA solution prepared in step 2 at a total flow rate of 40 mL / min.
[0544] 4. Collect the LNP mixture after the three-way connection and place it in a dialysis bag with a molecular weight cut-off of 100 KDa.
[0545] 5. The LNP mixture was dialyzed overnight against 50 mM Tris-buffered saline, pH 7.4.
[0546] 6. Sieving and subsequent measurement of the sieved LNPs to measure the PDI of the LNPs by dynamic laser light scattering; mRNA encapsulation efficiency and concentration by Ribogreen assay; and pKa by TNS-α assay.
[0547] The results are shown in Table 1 below.
[0548] Table 1 Performance parameters of lipid nanoparticles (LNPs) made from cationic lipids of the present disclosure
[0549] As can be seen from the results in the above table, the LNPs made from the cationic lipids disclosed herein have excellent drug encapsulation efficiency and can effectively achieve drug encapsulation for targeted delivery in vivo.
[0550] Animal studies
[0551] The encapsulated solution was administered to mice in the following manner, and its delivery efficiency in mice was tested. DLin-MC3-DMA (MC3) is a cationic liposome approved by the FDA in 2018 for the delivery of small nucleic acids. It has high nucleic acid drug delivery efficiency and biosafety, and is often used as the industry gold standard in cationic lipid screening. In mouse experiments, a ratio of nucleic acid delivery efficiency normalized to MC3 greater than 0.1 is considered a cationic lipid with high delivery efficiency.
[0552] Intramuscular administration
[0553] 1. Dilute the LNP solution to a concentration of 0.1 mg / mL mRNA with 50 mM TBS, pH 7.4.
[0554] 2. The mice involved in this study were female Balb / C, weighing 18-22 g, 6-8 weeks old, with 5 mice per group.
[0555] 3. Prior to injection, the dosing solution was kept at 4°C.
[0556] 4. Inject 50uL of LNP solution into the right thigh of the mouse.
[0557] 5. 6 h after injection, inject 200 μL of 1.5 mg / mL D-luciferin solution intraperitoneally into the mouse.
[0558] 6. Obtain in vivo luminescence images of mice using the IVIS system (Aniview).
[0559] 7. Measure the luminescence intensity of each mouse using Aniview software.
[0560] 8. MC3 lipid nanoparticles were used as a positive control. The in vivo efficacy of each cationic lipid tested was recorded as the fold change in luminescence intensity relative to MC3 (ratio normalized to MC3).
[0561] Intravenous administration
[0562] 1. Dilute the LNP solution to a concentration of 0.1 mg / mL mRNA with 50 mM TBS, pH 7.4.
[0563] 2. The mice involved in this study were female Balb / C, weighing 18-22 g, 6-8 weeks old, with 5 mice per group.
[0564] 3. Prior to injection, the dosing solution was kept at 4°C.
[0565] 4. Each mouse was given 0.06 mg / kg via tail vein injection.
[0566] 5. 6 h after injection, inject 200 μL of 1.5 mg / mL D-luciferin solution intraperitoneally into the mouse.
[0567] 6. Obtain in vivo luminescence images of mice using the IVIS system (Aniview).
[0568] 7. Measure the luminescence intensity of each mouse using Aniview software.
[0569] 8. MC3 lipid nanoparticles were used as a positive control. The in vivo efficacy of each cationic lipid tested was recorded as the fold change in luminescence intensity relative to MC3 (ratio normalized to MC3).
[0570] The results are shown in Table 2 below.
[0571] Table 2. In vivo delivery efficacy of lipid nanoparticles prepared from cationic lipids of the present disclosure
[0572] As can be seen from the results in the table above, the nucleic acid delivery efficiency of LNPs made from the cationic lipids of the present invention in mice is normalized to MC3 and is above 0.10, and can even reach a maximum of 9.31. Therefore, the cationic lipids of the present invention achieve good or even excellent targeted delivery of nucleic acid drugs in vivo.
[0573] Although the nucleic acid delivery efficiency of cationic lipids was tested using mRNA as an example in the present disclosure, the nucleic acid drugs adapted by the cationic lipids of the present disclosure are not limited thereto, but can be used to effectively deliver various nucleic acid drugs including but not limited to DNA drugs, RNA drugs, or both.
[0574] It is to be understood that the present invention is not limited to the particular embodiments of the invention described above, as variations may be made therein and still fall within the scope of the appended claims.
Claims
1. A cationic lipid having the following general formula (I): in, A is a nitro group; B is C 1-6 Alkyl, wherein the C 1-6 The alkyl group is optionally unsubstituted or substituted with 1-3 R d replace; C is -L 3 -Y 2 -L 4 -CH=CR 4 R 5 ,in L 3 and L 4 Each independently selected from a chemical bond and a linear or branched C 1-12 Alkylene, the C 1-12 Each occurrence of alkylene is optionally unsubstituted or substituted with 1-3 R e replace, Y 2 selected from -C(=X)-X-, -X-C(=X)-, -C(=X)-NH-, -NH-C(=X)-, -X-C(=X)-NH-, -NH-C(=X)-X-, -X-C(=X)-X-, -NH-C(=X)-NH- and -X-X-, and R 4 and R 5 Each independently selected from a linear or branched C 2-12 Alkyl, the C 2-12 The alkyl group is optionally unsubstituted or substituted with 1-3 R f replace; D is -L 5 -Y 3 -L 6 -R 6 ,in L 5 and L 6 Each independently selected from a chemical bond and a linear or branched C 1-12 Alkylene, the C 1-12 Each occurrence of alkylene is optionally unsubstituted or substituted with 1-3 R g replace, Y 3 selected from -C(=X)-X-, -X-C(=X)-, -C(=X)-NH-, -NH-C(=X)-, -X-C(=X)-NH-, -NH-C(=X)-X-, -X-C(=X)-X-, -NH-C(=X)-NH- and -X-X-, and R 6 Independently selected from saturated or unsaturated linear or branched C 6-18 Hydrocarbon or steroid group, the C 6- 18 The hydrocarbon or steroid group is optionally unsubstituted or substituted with 1-3 R h replace; Or, D is -L 3 -Y 2 -L 4 -CH=CR 4 R 5 ; Each occurrence of X is independently O or S, and R d 、R e 、R f 、R g and R h Each occurrence is independently selected from C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylamino, di(C 1-3 Alkyl)amino, C 1-3 Alkoxycarbonyl, C 1-3 Alkylcarbonyloxy, C 1-3 Alkylcarbonylamino, C 1-3 alkylaminocarbonyl, hydroxy, halo and cyano.
2. The cationic lipid of claim 1, wherein X is O.
3. cationic lipid as claimed in claim 2, wherein B is C which is unsubstituted or substituted with 1 to 3 substituents selected from hydroxy, halogen and cyano 2-4 alkyl.
4. cationic lipid as claimed in claim 3, wherein, B is selected from the group consisting of primary hydroxy-substituted methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl and tert-butyl.
5. cationic lipid as claimed in claim 1, wherein C is -L 3 -Y 2 -L 4 -CH=CR 4 R 5 ,in R 4 and R 5 are the same or different and are each independently selected from a linear C 2-12 alkyl.
6. cationic lipid as claimed in claim 1, wherein D is -L 5 -Y 3 -L 6 -R 6 ,and R 6 It is a straight or branched chain C containing one or two carbon-carbon double bonds. 6-18 Hydrocarbon group.
7. cationic lipid as claimed in claim 6, wherein R 6 A straight or branched C 6-18 Hydrocarbon group.
8. cationic lipid as claimed in claim 1, wherein D is -L 5 -Y 3 -L 6 -R 6 ,and R 6 To be C 1-6 Alkoxycarbonyl substituted C 6-18 alkyl.
9. cationic lipid as claimed in claim 1, wherein D is -L 3 -Y 2 -L 4 -CH=CR 4 R 5 ,in R 4 and R 5 are the same or different and are each independently selected from a linear C 2-12 alkyl.
10. The cationic lipid according to any one of claims 1 to 9, wherein L 3 、L 4 、L 5 and L 6 Each independently selected from a chemical bond and C 1-6 Alkylene, the C 1-6 Alkylene is optionally unsubstituted or substituted by 1-3 groups independently selected from C 1-3 Alkyl, C 1-3 Substituents include alkoxy, hydroxy and halogen.
11. The cationic lipid according to claim 10, wherein L 3 、L 4 、L 5 and L 6 Each independently selected from a chemical bond and unsubstituted C 1-6 Alkylene.
12. The cationic lipid according to any one of claims 1 to 10, wherein Y 2 and Y 3 Each is independently selected from -OC(=O)-, -C(=O)-O- and -OC(=O)-.
13. cationic lipid as claimed in claim 1, it has the structure selected from lower group:
14. A liposome comprising the cationic lipid according to any one of claims 1 to 13.
15. A lipid nanoparticle comprising the cationic lipid according to any one of claims 1 to 13.
16. Use of the cationic lipid according to any one of claims 1 to 13 for preparing liposomes.
17. Use of the cationic lipid according to any one of claims 1 to 13 for preparing lipid nanoparticles.
Citation Information
Patent Citations
Cationic lipid, liposome containing cationic lipid, nucleic acid pharmaceutical composition containing liposome, preparation and application of nucleic acid pharmaceutical composition
CN113402405A
Lipid nanoparticle composition
CN114206827A
Lipid membrane structure
JP2016084297A
Methods and compositions for delivery of active agents
US20130129785A1
Lipids and Lipid Compositions for the Delivery of Active Agents
US20160317458A1
